PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 1
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 
DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, 
TOLERABILITY, AND PHARMACODYNAMICS OF 
PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS 
WITH NONALCOHOLIC FATTY LIVER DISEASE 
Investigational Product Number: PF-05221304
Investigational Product Name: Not applicable
United States (US) Investigational New Drug (IND) Number:
European Clinical Trials Database (EudraCT) Number: 2017-001156-55
Protocol Number: C1171002
Phase: 2aCCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 2Document History
DocumentVersion 
DateSummary of Changes and Rationale
Amendment 
203 October
2017This amendment is making the following substantial changes to align with 
the Pfizer Enterprise-level revision to appropriate measures to prevent pregnancy in the population of childbearing potential enrolled who are sexually active and
align with the Clinical Trial Facilitation Group (CTFG) 
2014 European Guidance–
•Section 4.4.6 revised to –
1. Remove mandate to use highly effective contraception in female 
partners of male subjects of childbearing potential;
2. Use of male or female condom alone is viewed as an effective 
method of contraceptive but must continue to be used with another 
highly effective method of contraceptive;
•Language mandating use with spermicide has been removed 
since the intent is to combine use of condom with another highly-effective method of contraception;  
•The following administrative changes to enhance clarity and ensure 
intended interpretation of protocol content have also been incorporated –
•Section 4.2 , exclusion criterion #9, correct inconsistency and permit 
at both Pre-Qualification and Screen 1 visits (not only Screen 1)repeat laboratory-related assessments to assess eligibility and depict intent to exclude those who appear to have been cured of 
Hepatitis C viral infection by pharmacological intervention;
•Section 5.8.5 updated to remove use of symbol and replace with 
text to delineate that list of medications taken within ( not
prior to)
8 weeks of Visit 1 are prohibited;
•Section 5.8.5 updated to clarify that anti-convulsants specifically 
prescribed for management of seizures are not permitted (though 
use for other indications may be permitted); 
•Section 5.8.5 updated to clarify that β-blockers and calcium channel 
blockers are permitted, while other antiarrhythmic agents (eg, those that function primarily as sodium and potassium channel blockers)arenot
permitted; 
•Typographical error in Section 7.2.1 corrected to capture that 
Visit 11 is Week 16 ( notWeek 11);
•Figure 2 and Section 7.9.1 further clarified (beyond Enterprise-level 
text in Section 8.2.2 ) and by extension in Appendix 2 , that in those 
subjects with observed platelet count below lower limit of normal 
by Week 8, additional (unplanned) visits every two weeks should continue while on double-blinded investigational product (ie, add unplanned visits at Weeks 10, and 14, in addition to already scheduled visits at Weeks 12, and 16) with blood samples collected CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 3DocumentVersion 
DateSummary of Changes and Rationale
to permit safety-related laboratory parameters including hematology 
by sponsor identified central laboratory;
•Appendix 2 and Appendix 3 updated to reflect removal of 
“scheduled” as visits for assessment could also be unplanned.
Amendment 
124 July 
2017This amendment is making the following substantial changes as requested by 
the United States Food and Drug Administration (US FDA) as part of theirreview of the original protocol submitted on 11May2017 –
•In addition to conducting standard full and brief physical examinations, 
targeted physical examinations of skin, eyes, and pulmonary system were added at predose at Weeks 2, 8, and 16 – refer to Table 1 and
Section 7.2.1
•Section 3.2 updated to include explicit cross-reference to detailed 
Enterprise-level standardized management of AEs, SAEs, and cases of DILI;
•Section 3.3 updated to offer instances wherein unblinded safety review by 
IRC will be triggered based on-going blinded safety reviews by selected members of the Sponsors’ study team;
•Section 5.8.5 updated to exclude CYP3A4/5 substrates with narrow 
therapeutic indices  
•Section 7.9.3 expanded to include language expecting subjects with type 
2 diabetes mellitus to share the low blood glucose information sheet which delineates the symptoms of hypoglycemia along with treatment options with their family member(s) / roommate(s) to help in their 
management of hypoglycemia;
•While PF-05221304 is not known to carry the potential risk of 
hypoglycemia, many of the agents used for the management of glycemic control in patients with T2DM carry this risk - this rationale this added to Section 1.3.2 ;
•In addition
, based on determination by the Central IRB for sites in 
Canada and USA, that informed consent must be offered by the participating subject only,
via this amendment, at the study-level, a 
requirement is being instituted that informed consent for both pre-qualification and main study, be offered by the participating subject,
only
•The provision that permits subjects’ legally acceptable representative
to offer informed consent has been deleted (in Sections 4.1 , 8.1.2 , 8.1.4 , and12.3).
•Administrative clarifications added to Section 7.1.2 regarding 
FibroScan
®operators; and Appendix 4 to capture time of onset and 
resolution of hypoglycemic event rather than time to recovery to match 
Sponsors’ new standard for capture of these events.
Original 
protocol04 May
2017Not applicable 
This amendment incorporates all revisions to date, including amendments made at the request of country health 
authorities and institutional review boards (IRBs)/ethics committees (ECs).  CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 4TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....8
LIST OF FIGURES ................................................................................................................ ...8
APPENDICES ..................................................................................................................... ......8
PROTOCOL SUMMARY.......................................................................................................101. INTRODUCTION ...............................................................................................................1 6
1.1. Mechanism of Action/Indication.............................................................................161.2. Background .............................................................................................................16
1.2.2. Clinical Experience with PF-05221304......................................................19
1.3. Rationale for Study..................................................................................................20
1.3.1. Rationale for Design...................................................................................201.3.2. Rationale for Population Enrolled ..............................................................221.3.3. Rationale for Doses Selected ......................................................................26
1.4. Summary of Benefit Risk Assessment....................................................................28
2. STUDY OBJECTIVES AND ENDPOINTS.......................................................................283. STUDY DESIGN................................................................................................................ .30
3.1. Study Ov erview.......................................................................................................30
3.2. Stopping Rules for Dosing in Individual Subjects ..................................................313.3. Considerations for Pausing or Stopping Active Dose(s) Based on Observed 
Safety......................................................................................................................... 32
4. SUBJECT ELIGIBILITY CRITERIA.................................................................................33
4.1. Inclusion Criteria.....................................................................................................33
4.2. Exclusion Criteria....................................................................................................364.3. Randomization Criteria ...........................................................................................404.4. Lifestyle Requirements ...........................................................................................41
4.4.1. Dietary Restrictions ....................................................................................414.4.2. Alcohol, Caffeine, and Tobacco .................................................................424.4.3. Activity .......................................................................................................424.4.4. Confinement to Site ....................................................................................424.4.5. Confinement at Imaging facility.................................................................43CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendm ent 2, 03 October 2017
Page 54.4.6. Contraception ..............................................................................................43
4.5. Sponsor’s Qualified Medical Personnel ..................................................................45
5. STUDY TREATMENTS .....................................................................................................45
5.1. Allocation to Treatment
..........................................................................................46
5.2. Breaking the Blind
..................................................................................................46
5.3. Subject Compliance .................................................................................................46
5.4. I nvestigational Product Supplies .............................................................................47
5.4.1. Dosage Form(s) and Packaging
..................................................................47
5.4.2. Preparation and Dispensing ........................................................................47
5.5. Administration .........................................................................................................47
5.6. I nvestigational Product Storage ..............................................................................48
5.7. I nvestigational Product Accountabilit y
...................................................................49
5.7.1. Destruction of Investigational Product Supplies
........................................49
5.8. Concomitant Treatment(s) .......................................................................................49
5.8.1. Medications for Glycemic Cont
rol.............................................................49
5.8.2. L
ipid-modify ing medications .....................................................................50
5.8.3. Medications for Controlling Blood Pressure
..............................................51
5.8.4. Other Acceptable Concomitant Medications ..............................................51
5.8.5. Prohibited Medications
...............................................................................52
5.9. Rescu
e Medication ..................................................................................................53
6. STUDY PROCEDURES
.....................................................................................................53
6.1. Proposed Chronology of Procedures .......................................................................53
6.2. Pre -Qualification .....................................................................................................54
6.3. Screening (Visits 1 and 2)
.......................................................................................54
6.4. Visit 3 (Run -
in) through to Visit 11 (Week 16) ......................................................55
6.5. Follow -up Visit .......................................................................................................55
6.6. Subject Withdrawal / Early  Termination ................................................................55
7. ASSESSMENTS ..................................................................................................................57
7.1. L iver Assessments using FibroScanand MRI
-PDFF ...........................................57
7.1.1. Background on Liver Assessment Tech niques ...........................................57
7.1.2. Assessment of L iver Fat and Stiffness –using FibroScan.......................58
7.1.3. Assessment of L iver Fat Using MRI -PDFF Acqui sition and Analy sis......58

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 67.1.4. Analysis of MRI-PDFF Images Including Determination of 
Eligib ility .........................................................................................................59
7.2. Safety-Related Assessments....................................................................................60
7.2.1. Physical Examination .................................................................................60
7.2.1.1. Measurement of Waist Circumference......................................61
7.2.2. Body Weight...............................................................................................617.2.3. 12-lead Electrocardiogram..........................................................................627.2.4. Blood Pressure and Pulse Rate ...................................................................62
7.3. Clinical Labor atory Tests ........................................................................................63
7.3.1. Pregnancy Testing ......................................................................................65
7.4. Rater Qualifications.................................................................................................657.5. Pharmacokinetics – plasma for analysis of PF-05221304 ......................................657.6. Exploratory Biomarkers ..........................................................................................66
7.8. Blood Volume .........................................................................................................68
7.9. Specific Subject Safety Scenarios ...........................................................................69
7.9.1. Potential Cases of Thrombocytopenia ........................................................697.9.2. Potential Cases of Hypertriglyceridemia ....................................................697.9.3. Management of Glycemic Control in Patients with T2DM........................69
7.9.3.1. Protocol-Specific Criteria for Inadequate Glycemic 
Control...............................................................................................70
8. ADVERSE EVENT REPORTING......................................................................................72
8.1. Requirements...........................................................................................................73
8.1.1. Additional Details on Recording Adverse Events on the CRF...................748.1.2. Eliciting Adverse Event Information..........................................................748.1.3. Withdrawal from the Study Due to Adverse Events (see also Section 
6.6) ...................................................................................................................74
8.1.4. Time Period for Collecting AE/SAE Information......................................74
8.1.4.1. Reporting SAEs to Pfizer Safety...............................................758.1.4.2. Recording Non-serious AEs and SAEs on the CRF .................75
8.1.5. Causality Assessment .................................................................................75CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 78.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities ..................75
8.2. Definitions............................................................................................................... 76
8.2.1. Adverse Events ...........................................................................................768.2.2. Abnormal Test Findings .............................................................................768.2.3. Serious Adverse Events ..............................................................................778.2.4. Hospitalization............................................................................................77
8.3. Severity Assessment................................................................................................798.4. Special Situations ....................................................................................................79
8.4.1. Protocol-Specific Serious Adverse Events .................................................798.4.2. Potential Cases of Drug-Induced Liver Injury............................................798.4.3. Exposure to the Investigational Product During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................81
8.4.3.1. Exposure During Pregnancy......................................................818.4.3.2. Exposure During Breastfeeding ................................................828.4.3.3. Occupational Exposure .............................................................82
8.4.4. Medication Errors .......................................................................................83
9. DATA ANALYSIS/STATISTICAL METHODS...............................................................83
9.1. Sample Size Determination.....................................................................................849.2. Efficacy Analysis ....................................................................................................84
9.2.1. Analysis of the Primary Endpoint...............................................................849.2.2. Analysis of Sec ondary Endpoint ................................................................85
9.3. Analysis of Ter tiary Endpoints ...............................................................................85
9.3.2. Other Tertiary Endpoints ............................................................................85
9.4. Safety Analysis........................................................................................................86
9.5. Interim An alysis ......................................................................................................86
9.6. Data Monitoring Committee ...................................................................................86
10. QUALITY CONTROL AND QUALITY ASSURANCE.................................................8611. DATA HANDLING AND RECORD KEEPING .............................................................87
11.1. Case Report Forms/Electronic Data Record .........................................................8711.2. Record Retention...................................................................................................88
12. ETHICS..................................................................................................................... .........88
CCI
PF-05221304 
C1171002
FINAL Protocol Amendm ent 2, 03 October 2017
Page 812.1. I nstitutional Review Board/Ethics Committee ......................................................88
12.2. Ethical Conduct of the Study ................................................................................88
12.3. Subject I nformation and Consent ..........................................................................89
12.4. Reporting of Safet y Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................89
13. DEFI NITION OF EN D OF TRIAL ...................................................................................90
13.1. End of Trial in a Member State
.............................................................................90
13.2. End of Trial in All Oth er Participating Countries .................................................90
14. SPONSOR DI SCONTI NUATION CRITERIA ................................................................90
15. PUBLICATION OF S TUDY RESUL TS..........................................................................90
15.1. Communication of Results by  Pfizer ....................................................................90
15.2. Publications by  Investigators ................................................................................91
16.REFERENCES ..................................................................................................................93
LIST OF TABLES
Table 1. Study -Related Procedures in C1171002 ...............................................................14
Table 2. Study -Related Blood and Urine Collections in C1171002 ...................................15
Table 3. Randomized Regimens in Study  C1171002 .........................................................46
Table 4.
All Planned Safety -Related Laboratory  Tests and Exploratory  Biomarkers 
in Study  C1171002 ...............................................................................................64
LIST OF FIGURES
Figure 1. Overview of C1171002 Study  Population ............................................................23
Figure 2. C1171002 Study  Design .......................................................................................31
Figure 3. Two-Tiered Stratification in Study  C1171002 ................................ ..................... 41
APPEN DICES
Appendix 1. Abbreviations ......................................................................................................95
Appendix 2. Guidance to I nvestigators –Management of Individual Subjects With 
Decrease in Platelet Count ................................ ................................ .................... 99
Appendix 3. Guidance to I nvestigators –Management of Individual Subjects With 
Elevation in Fasting Serum Tri glycerides ................................ .......................... 100

PF-05221304 
C1171002
FINAL Protocol Amendm ent 2, 03 October 2017
Page 9Appendix 4. Guidance to I nvestigators – Capturing Details for Episodes of 
Hypoglycemia in Patients with T2DM...............................................................101

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 10PROTOCOL SUMMARY
Background and Rationale: The current study is the first clinical trial proposed with 
PF-05221304 in adult subjects with NAFLD.  The investigational product will be administered orally, once-daily for up to 16 weeks.  It is designed as a dose-ranging trial with placebo and 4 active doses of PF-05221304 to assess the safety, tolerability and the effect of PF-05221304 on liver fat.  In addition, asse ssment of the effect of PF-05221304 on other 
pharmacodynamics/ exploratory parameters is planned.
Objectives and Endpoints: 
Primary Objective: Primary Endpoint:
To evaluate the dose-response for the effect on liver 
fat with a range of PF- 05221304 doses administered 
daily in adults with nonalcoholic fatty liver disease 
(entire study population)Percent change from baseline in liver fat, as assessed 
using MRI-PDFF, at Week 16
Secondary Objective(s): Secondary Endpoint(s):
To evaluate the dose-response for the effect on ALT 
with a range of PF- 05221304 doses ad ministered 
daily in the 1sttier stratification comprising of adults
with diagnosed/presumed nonalcoholic 
steatohepatitis, onlyPercent change from baseline in ALT, at Week 16
To evaluate the safety and tolerability of a range of 
PF-05221304 doses administered daily in adults 
with nonalcoholic fatty liver disease (entire study 
population)Assessment of TEAEs, safety-related clinical 
laboratory tests, vital signs, and 12-lead ECGs 
Tertiary Objective(s): Tertiary Endpoint(s):
To evaluate the dose-response for the effect on liver fat, over time , with a range of PF-05221304 doses 
administered daily in adults with nonalcoholic fatty 
liver disease (entire study population)Percent change from baseline in liver fat, as assessed 
using MRI-PDFF, over time up to Week 16
To evaluate the dose-response for the effect on key liver function tests and NASH-related biomarkers over time , with a range of PF-05221304 doses 
administered daily in the 1
sttier stratification
comprising of adults with diagnosed/presumed 
nonalcoholic steatohepatitis, onlyPercent change from baseline, over time up to 
Week 16, for:
•ALT, AST, Alkaline Phosphatase, GGT
•CK18-M30 and CK18-M65
•Pro-C3 & Pro-C6CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 11Tertiary Objective(s): Tertiary Endpoint(s):
To evaluate the dose-response for the effect on other 
potentially mechanism-related parameters and metabolic parameters, over time , with a range of 
PF-05221304 doses administered daily in adults with nonalcoholic fatty liver disease (entire study 
population)Percent change from baseline, over time up to 
Week 16, for: 
•Potentially mechanism-related parameters –
−Serum apolipoprotein A1, B (total), C3, E
•Metabolic parameters –
−HbA1C
−Fasting lipid panel (fasting total cholesterol, 
direct LDL-C, HDL-C, triglycerides, VLDL)
To evaluate the dose-response for the effect on glycemic parameters, over time , with a range of 
PF-05221304 doses administered daily in the 2
ndtier 
stratification comprising of adults with T2DM, onlyChange from baseline, over time up to Week 16, for: 
•HbA1C
•FPG
•FPI
•HOMA-IR
For allendpoints, baseline defined as result closest prior to dosing at Visit 5 (Day 1); for list of terms corresponding to 
the abbreviations used herein, refer to Appendix 1 .CCI
CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendm ent 2, 03 October 2017
Page 12Study Design: This is a randomized, double -blind, p lacebo -controlled, 5-arm(placebo, plus 
4active doses of PF-05221304 ), parallel -group study .  The overall study  desig n is 
summarized in the figure below:
Baseline
(V4)
Day 1 = Randomization
(V5)
8-weeks and 14-weeksStabilize
background 
medications
Treatment with double -dummy, blinded medication 
(placebo, or1 of 4 doses PF-05221304)PBO
only
Screen 1 
(V1)
Screen 2 
(V2)
On-site FU (V12) 
[10±4 days post last dose]Day 14 
± 4
(V6)Day 28 
± 4
(V7)Day 42 
± 4
(V8)Day 56 
± 4
(V9)Day 108 
± 4
(V11)Continue re-stabilized background medications
[Telephone] Contact  FU 
[28&35days post last dose]Day 84 
± 4
(V10)Pre-Qualification Run-in 
(V3)Account for majority of placebo -
response related to increased 
compliance once in trial
Confirm subject can comply 
with IP dosing instructions 
prior to randomization 
(≥ 90 % compliance over 
14±2 day s)
Visits every  2 weeks up to V9
considering prior limited clinical experience Visit at Day 108 acknowledging dosing in 
16-wktox-was upto Day 112 plus intent to 
complete V11procedures while on IP
Each visit represents an outpatient visit to the site or Imaging facility and envisioned to last ≤ 2 -hours
Liver Imaging via MRI -PDFF expected at Screen 2 [eligibility for study; centrally read], Baseline between V4and V5, plus V7, V10, V11
Assessment using FibroScan®to occur at pre -Qualification + Screen 1 andthen at Baseline between V4 and V5, plus V7, V10, V11
Ifat V9 platelet count is observed to be below lower limit of normal as reported by sponsor- identified central laboratory, additional 
(unplanned) visits should occur –refer to Appendix 26-weeks
Study Treatments: Each dose will consist of 3 tablets (1 tablet from each of the 3 bottles 
dispensed) as outlined below:
Regim en Regim en Description 
(dosed once -daily)Number of PF -05221304 tablets Number of 
PF-05221 304-matching 
placebo tablets
1 m
g5 m
g25mg 50m
g1/ 5mg 25/ 50mg
A Placebo - - - - 2 1
B PF-05221304 – 2mg 2 - - - - 1
C PF-05221304 –10mg - 2 - - - 1
D PF-05221304 –25mg - - 1 - 2 -
E PF-05221304 –50mg - - - 1 2 -
Study Population: In the Phase 2a stud y,the entire stu dy population will have NAFLD 
(liver fat  8% b y MRI -PDFF as part of screening assessment) and features of metabolic 
syndrome.  T he population enrolled will be stratified into two sub- populations as follows:

PF-05221304 
C1171002
FINAL Protocol Amendm ent 2, 03 October 2017
Page 13Subjects wi th diagnosed or presumed NASH: These subjects would either have 
been diagnosed with NASH on liver biopsy (within the prior  24months) orwould 
meet imaging and clinical characteristics highly  suggestive of NASH in the absence 
of a liver biops y;
Subjects with NAFLD with likely minimal inflammation and fibrosis :These 
subjects will be classified based on evidence of ALT1.25x upper limit of normal 
reference range (ULN) for the sponsor -identified central laboratory , and no/minimal 
evidence of liver fibrosi s (as measured by  Vibration -Controlled Transient 
Elastograph y [VCTETM]and reported as liver stiffness measure [LSM, in kilopascals, 
kPa]using FibroS can).  This population is conside red a distinct, albeit related
population ,
to those categorized as diagn osed/presumed NASH; and included as a 
means to more broadl y assess general safet y (including potential mechanistic effects 
on platelets) and additional pote ntial beneficial effects of ACC inhibition (such as 
improvement in gly cemic control), then could be readil y achieved via limiting the 
population to only  subjects with NASH. 
In each arm ,50% of subjects randomized will be deemed to be eligible for the 
sub-population classified as diagnosed/presumed NASH; with the remaining subjects per arm 
eligible for the stratum defined as NAFLD with likely  minimal inflammation and fibrosis.
Statistical Methods: The proposed sample size for this study  is approximately  360 subjects
randomized (72subjects per arm) to ensure at least 
300subjects (60 subjects per arm)
complete the study .  The sample size of a minimum of 60 completers per arm, was calculated 
to yield  80% power to detect a placebo-adjusted, percent change from baseline of 30% in 
liver fat (in entire stud y population and in n=30/arm in each sub -populati on of the 1sttier 
stratification), using a 1 -sided, t -test at level 10%.  For the secondary  endpoint of ALT in the 
1sttier stratification sub -population of diagnosed/presumed NASH, the sample size of a 
minimum of 30 completers per arm was calculated to yield  80% power to detect a 
placebo- adjusted, percent change from baseline in AL T of 35%, using a 1 -sided, t -test at 
level 10%.
For the primary  and key  secondary  endpoint of placebo -adjusted, percent cha nge from 
baseline in liver fat via MRI -PDFF (in entire study  population) and ALT (in the 
sub-population of diagnosed/presumed NASH) at Week 16, a mixed model repeated measure 
(MMRM) anal ysis will be performed with treatment, time and treatment -by-time interaction 
as fixed effects, and subject as a random effect. Descriptive summaries of the observed 
values and percent change from baseline in liver fat in each treatment group at each time 
point will be produced.  For statistical analy ses, 80% confidence intervals will be pro duced 
for the least -square mean differences in each treatment group as compared to placebo.  One 
sided p
-values will be display ed for the comparison against placebo with no multiplicity  
adjustment made.
Similar analy ses will be applied to continuous secondary  and tertiary  endpoints, as 
appropriate t o the data.  Descriptive summaries will be display ed for categorical secondary  
and tertiary  endpoints. 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 14SCHEDULE OF ACTIVITI ES: TABLE 1and TABLE 2provide an overview  of the protocol visits and procedures.  Refer to Section 6 and Section 7of 
the protoco l for detailed information on each procedure and assessment required for compliance with the protocol .The investigator may schedule unplanned 
visit(s)inaddition to those listed in Tables 1 and 2, in order t o conduct evaluations or assessments required to protect the w ell-being of the subject.
Table 1. Study -Related Procedures in C1171002
Visit Identifier
[for abbreviations refer to Appendix 1]
Pre-
Qualification
Screen 1
Screen 2
Run-inBaselineTreatm ent Phase [all procedures before morning dose of 
blinded IP, except liverfat & stiffness assessment s]Follow -up
Early 
TerminationWeeks Relative to Dosing on Day 1 -2 0 2 4 6 8 12 16 17-18 20a
Days relative to Dosing on Day 1 -142 1 144 284 424 564 844 1084 -- --
Visit 12 3 4 5 6 7 8 9 10 11 12 --
Informed consent (x2b) & demography x x
(Update) M edical & Medication history x x x x x x x x x x x x x x
Liverfat & stiffness (via FibroScan)cx x xdx x xd
Liver fat (via MRI -PDFF)exfxdx x xd
Physical Examgx x x x x x x x
Assess alcohol intake (AUDIT questionnaire) x x xhx
Assess correct use of contraception x x x x x x x x x x x x
Counseling on diet/exercise guidelines x x
Train on use and d ispense glucometer & ancillary 
supplies (T2DM subjects , only)x
Open -ended inquiry for adverse e vents x x x x x x x x x x x x x x x
Body w eight (+ hula -hoop test at pre-Q) x x x x x x x x x x x
Single supine 12-lead ECG x x x x x x x x x x x x
Single seated vitals (BP & pulse rate) x x x x x x x x x x x x
Registration in trial (via IRT) x x
Randomization in trial ( via IRT) x
Dispensationi(via IRT) of IP x x x x x
Witnessed dosing on site of IP x xhx x x x x x
Compliance via pill count on site of returned IP xhx x x x
Continued administration of IP xixi     xjxj
a.Tooccur via telephone contact (unless local regulations dictate on -site visit); regardless , on-site visit to be considered for follow -up of open TEAEs and/or abnormal laboratory tests
b.Subjects to provide consent for pre -qualification first; and on ce deemed likely eligible requested to provide separate consent for main study (V1 and on)
c.Assessment to be performed following 4-hr fast, at site (as part of site visit) or separate visit (s)to Imaging facility ; attempts to be made to stay within 2-hrwindow of V1 time 
d.Assessment to be performed on any day between V4 & V5 (ie, Baseline); and while subject is taking blinded I P with previous dose 24-hr prior (at V11) 
e.Assessment to be performed following 4-hr fast, via separate visit (s)to Imaging facility ; attempts to be made to stay within 2-hr window of V2 time
f.A single repeat assessment permitted as determined by sponsor -identified central imaging vendor; subject must notprogress to V3 until results from screen -repeat confirm eligibility
g.Includes arm circumference (at pre -Q); height plus waist circumference (at pre -Q &V1); targeted PE at V6, V9 , V11 and brief PE foropen AEs/abnormal tests , at investigator discretion 
h.Review of AUDIT questionnaire responses must be deemed acceptable, and90% compliance (with pills in each bottle) ,required to progress to randomization
i.At V4, reflects single -blind placebo; from V5 onwards, reflects double -blind randomized regimen
j.At V11 and ET visits reflects return to site of any remaining unused double -blind randomized regimen; subjects will notbe offered I P post last dose in this trial 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 15Table 2. Study-Related Blood and Urine Collections in C1171002
Visit Identifier
[for abbreviations refer to Appendix 1 ]
Pre-
Qualification
Screen 1
Screen 2
Run-inBaselineTreatment Phase [all procedures before morning dose of 
blinded IP, except when specified otherwise]Follow-up
Early 
TerminationWeeks Relative to Dosing on Day 1 -2 0 2 4 6 8 12 16 17-18 20a
Days relative to Dosing on Day 1 -14±±2 1 14±4 28±4 42±4 56±4 84±4 108±4 -- --
Visit 12 3 4 5 6 7 8 9 10 11 12 --
Blood collection, after ≥8-hour overnight fast, for – [refer also to Table 4 for comprehensive list of analytes]
−Hematology, chemistry, coagulation, HbA1C xbxb
No Blood orUrine Collectionsx xxxxxx xx xdx
−Fasting lipid panel xbxbxcxxxxxx xx xdx
−Pregnancy (females only) xbxbxcxx x x x xdx
−FSH (females only), Serology (HBsAg, 
HBcAb, HCVAb, HIV), α1-antitrypsin, 
ceruloplasminxbxb
−% carbohydrate deficient transferrin xbxbxx x
−Apolipoproteins x x x x x x
−CK18-M30, CK18-M65, Pro-C3, and Pro-C6 x x x x x x
Spot urine collection for –
−Urine drug test xbxbxc
−Urinalysis (and microscopy, as appropriate) xbxbx xxxxxx xx xdx
−On-site pregnancy test (WOCBP, only) xgxgxgxgxgxgxxdx
a. To occur via telephone contact (unless local regulations dictate on-site visit); regardless , on-site visit to be considered for follow-up of open AEs and/or abnormal laboratory tests
b. Test results must be reviewed by a medically qualified site staff and deemed acceptable before progression to next visit (pre-Q results prior to V1; and V1 results prior to V2)
c. Test results must be reviewed by a medically qualified site staff and deemed acceptable before progression to randomization and first dose of double-blinded IP, at V5
d. Collections to occur only if visit is an on-site visit; collections to be skipped if visit is via telephone contact
f. If not collected on the designated collection day, collect at the next available time point when biospecimens are being colle cted in conjunction with a subject visit
g. At each of these visits , the test result must be reviewed by a medically qualified site staff and deemed acceptable, in order to continue participatio n in studyCCI CCI
CCI CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 161. INTRODUCTION
Acet yl-CoA carboxy lase (ACC) is a biotin carboxy lase that catal yzes the a denosine 
triphosphate (ATP) dependen t condensation of acety l-CoA and carbonate to form 
malony l-CoA.1The malony l-CoA produced by  ACC serves two major physiologic 
functions.  I t is an essential and rate -limiting substrate for de novo lipogenesis ( DNL) and it 
acts as an allosteric inhibitor of the enzy me carnitine -palmitoy ltransferase 1 (CPT -1).  
CPT-1is responsible for the transport of long -chain fatty  acyl-CoAs across the mitochondrial 
membrane into the mitochondria where they  become available fo r fatt y acid oxidation.  The 
transport step is rate -determining for this process.  Thus, ACC is positioned as a key  
physiologic switch regulating the transition from oxidative to lipogenic metabolism.  
Reducing malony l-CoA production via ACC inhibition is expected to inhibit simultaneously  
the de novo synthesis of fatty  acids and to increase flux through CPT -1leading to increased 
-oxidation of long- chain fatty  acids.  There are two closel y related isoforms of ACC, ACC1, 
and ACC2, encoded b y separate gene products that differ in tissue and cellular distribution. 
PF-05221304 is a potent, selective, orally bioavailable, and reversible dual ACC1/2 inhibitor 
designed to have as ymmetric distribution to the liver ,with ≥ 100 fold as ymmetric hepatic 
distribution demonstrated in both rats and monkeys; as such PF -05221304 is expected to 
inhibit DNL  and stimulate fatt y acid oxidation in the liver to a greater extent than in 
peripheral tissues.  In humans, administration of PF -05221304 has been shown to suppress 
hepat ic DNL in a Phase 1 trial in healthy  subjects; in addition, the drug is expected to 
stimulate hepatic fatt y acid oxidation, and consequently reduce fat accumulation in the liver.  
This inhibition of hepatic DNL is postulated to result in a decrease and nor malization of the 
excessive DNL observed in nonalcoholic fatty liver disease (NAFLD).  In addition, t he 
inhibition of ACC via administration of PF -05221304 also has the potential for 
anti-inflammatory  effects in nonalcoholic steatohepatitis (NASH). 
The current study  is the first clinical trial proposed with PF -05221304 in adult subjects with 
NAFL D.  The investigational product will be administered orall y, once -daily  for up to 
16weeks .  It is designed as a dose -ranging trial with placebo and 4 active doses of 
PF-05221304 to assess the safet y, tolerability  and the effect of PF -05221304 on liver fat .  In 
addition, assessment of the effect of PF -05221304 on other pharmacod ynamics/exploratory 
parameters is planned
.
1.1. Mechanism of Action/ Indication
PF-05221304 is a potent, selective, orally  bioavailable, and reversible dual ACC1/2 inhibitor, 
designed to have as ymmetric distribution to the liver.  It is being developed for the treatment 
of NASH with fibrosis .
1.2.Background
The World Health Organization lists NAFLD and NASH as the most important of conditions 
contributing to the global health burden due to liver diseases, with NASH acknowledged as a 
potentially  fatal condition leading to cirrhosis, liver failure, and hepatocellular carcinoma 
(HCC).2NASH is diagnosed clinically  by liver biopsy  demonstrating steatosis, 
inflammation ,and cy tological ballooning of liver hepatocy tes, often with vary ing degrees of 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 17fibrosis.  NASH progresses with increasing degrees of fibrosis, with cirrhosis developing in a 
subset of patients3with the most common complication of cirrhosis being HCC.4Patients 
with NASH may  be as ymptomatic or have non -specific symptoms such as fatigue, despite 
having significant disease on liver biopsy  and associated risk for progression to cirrhosis and 
liver-related mortality .
NASH is a clinical and histological subset of NAFL D (defined as presence of  5% hepatic 
steatosis) that is associated with increased all -cause mortality , cirrhosis and end- stage liver 
disease, increased cardiovascular mortalit y, and increased incidence of both liver related and 
non-liver related cancers .3Ina recent meta -analysis, the global prevalence of NAFLD is 
estimated at 25%, with the prevalence of NASH in the subset with biopsy -
proven NAFLD 
assessed at 59% .5The majority  of the population with NAFL D has si mple steatosis which 
has, in general, a benign clinical course.  A proportion of patients with NAFL D progress to 
having hepatocellular ballooning and lobular inflammation –taking close to a decade to 
progress from 1 stage to the next and 30-40 years to de velop cirrhosis; however, a smaller 
subset of patients progress very  rapidl y (within 10 years) to liver cirrhosis from NAFL D.6
The 5 -year (67%) and 10 -year (38%) survival rates in patients with NASH is signific antly  
different than in those with NAFL D.7The pooled liver -specific and overall mortality  
incidence rate estimates among those wi th NAFLD were calculated at 0.8 and 15.4, 
respectivel y, per 1,000 person -years. In contrast, amongst the population with NASH, the 
incidence rate e stimates were 11.8 (liver -specific) and 25.6 (overall) mortality .5
Alterations in lipid metabolism have been h ypothesized to contribute to the molecular 
pathogenesis of NAFLD and NASH.  Elevated rates of hepatic DNL have been reported to be 
a distinctive characteristic of NAFLD (defined as liver fat 5%).8Humans with elevated 
liver fat have a greate r than 3 -fold increase in the rate of hepatic DNL relative to subjects 
with normal liver fat, but differences between the groups were not detected in adipose free 
fatty acid (FFA) flux or in production of very  low density  lipoprotein (VLDL) from FFAs.  
Consequently , when comparing human subjects with steatosis to those with normal liver fat, 
the contribution of hepatic DNL was most significantly elevated in subjects with high liver 
fat.8ACC inhibition is expect ed to suppress hepatic DNL  and stimulate hepatic fatt y acid 
oxidation, and consequently  reduce steatosis.9Partial inhibition of this enzyme activity  
would be expected to lead to such improvements, with 70% hep atic DNL inhibition 
normalizing the elevated flux in subjects with NAFLD to that observed in individuals with 
normal liver fat.8Consistent with this, beneficial effects of pharmacological ACC inhibition 
on liv er fat in rodent models of NAFLD/NASH have been reported.9,10,11,12
Emerging data also suggest that suppression of DNL  through ACC inhibition may  also 
directly  reduce inflammation by  restraining the formation of the inflammatory  
interleukin -17 secreting T cells of the T helper 17 lineage (T h17) cells which in turn promote 
the deve lopment of anti
-inflammatory  Foxp3(+) regulatory  T (Treg) cells.13Studies 
comparing patients with NASH versus those with simple steatosis or healthy  liver have 
demonstrated that progression from NAFL D to NASH is marked b y a higher frequency of 
Th17 cells in the liver and increase in the ratio of Th17 cells to Treg cells in peripheral blood 
and in the liver.14

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 18CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 191.2.2. Clinical Experience with PF-05221304
As of May-2017, a single clinical study (C1171001) has been conducted with PF-05221304.  
A total of 96 (93 male and 3 female) healthy adult subjects were randomized in this one study.  Overall, 82 subjects (85%) have been exposed to at least a single oral dose of PF-05221304; with 56 of these subjects exposed to repeated doses of PF-05221304 for up to 14-days.  Of these, 16 subjects received single oral doses of PF-05221304 ranging from 1 mg to 240 mg – with each single dose of PF-05221304 evaluated in at least 6 subjects.  An additional 70 subjects were exposed to up to 14-days of repeated oral dosing of PF-05221304 (n=56 subjects; up to 8 subjects per dose) or placebo (n=14 subjects, total) ranging from total daily doses of 2 mg/day to 200 mg/day – administered every 12 hours (Q12H) in 5 cohorts and once-daily (QD) in 2 cohorts – to assess safety, pharmacokinetics (PK), and steady-state effect on marker of target engagement (ie, inhibition of DNL).  Ten more subjects received single oral dose (100 mg) in 2 periods with and without a high-fat/high-caloric morning meal to assess the effect of food on plasma exposure of PF-05221304. 
In Study C1171001, single oral doses (up to 240 mg) and repeated total daily doses (up to 
200 mg/day) were found to be well tolerated with an acceptable safety profile.  Over this dose range evaluated, while the maximum tolerated dose (MTD) was not
identified, higher 
doses were not assessed either because the a priori identified PK stopping limit was achieved (single dose) or
near complete inhibition of hepatic DNL was observed (upon repeated 
dosing). 
In the clinical program to date, there have been no serious adverse events (SAEs), 
no treatment-emergent adverse events (TEAEs) of ‘severe’ intensity, and no apparent dose-related increase in frequency or severity of TEAEs across the 240-fold (single) and 100-fold (repeated) dose range studied.  All of the TEAEs were ‘mild’ in intensity except 1 TEAE of ‘platelet count decreased’ deemed to be of ‘moderate’ intensity; this resulted in premature withdrawal of 1 subject following 13 (of 14) days of PF-05221304 dosing at 100 mg Q12H (200 mg/day), the highest repeated dose evaluated.  This ‘moderate’ intensity TEAE comprised of a gradual decline in platelet count from a baseline of 167,000/mm
3to 
114,000/mm3at 24-hours post last dose (on Day 13).  This subject was asymptomatic with no 
signs or symptoms of platelet dysfunction and the decrease in platelet count did not meet 
criteria for thrombocytopenia (defined as < 100,000/mm3).  The platelet count increased
towards baseline by 72 hours post last dose and was back to baseline by 10 days post last dose.
Upon repeated dosing, the only TEAE reported by more than 2 subjects exposed to 
PF-05221304, across the entire dose range evaluated, was headache.   
 
  Of note, no dose related trends in venipuncture bruising-related TEAEs 
(eg, contusions) were noted despite 51 direct venipunctures (for serial blood collections) performed per subject during the inpatient stay phase of the repeated dosing portion of this study. CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 20Across the other safety-related data collected, some asymptomatic, drug-related, laboratory 
parameter changes were observed.  This included a gradual increase in fasting and post-prandial serum triglycerides with repeated doses ≥40 mg/day with effect plateauing 
over the 14-day dosing period.  
 
  At the 
doses ≥60 mg/day, a gradual decrease in platelet count was observed with repeated doses 
over the 14 day dosing period. This observation was not noted at PF-05221304 doses up to 40 mg/day and no signs or symptoms of platelet dysfunction were apparent based on the safety assessments performed.  There were no apparent abnormalities noted in the other safety-related assessments such as blood pressure, and cardiac conduction intervals [assessed on 12-lead electrocardiograms (ECGs)]. 
The plasma PK of PF-05221304 following oral administration suggests a moderate rate of 
absorption with a median time to maximum plasma concentration (T
max) ranging from 3 to 
5 hours, following repeated dosing with the morning meal.  Food (high-fat/high-caloric meal) had no clinically relevant effect on exposure which decreased slightly (area-under-the-curve to infinity (AUC
inf) by ~10% and C maxby ~25%, while rate of absorption was delayed with 
Tmaxof 2.5 hours (dosing in fasted state) moving out to 5 hours (when dosing occurred with 
food).  After attainment of C max, the disposition of PF-05221304 showed a decline with the
half-life of PF-05221304 being independent of dose, and ranging from approximately 13 to 18 hours.  With Q12H dosing frequency, an approximate 2-fold accumulation was observed which reduced to approximately 1.5-fold with QD dosing frequency. Across the range of repeated doses evaluated (2 mg/day to 200 mg/day), the plasma exposure increased approximately dose-proportionally with increasing dose.  Less than 1% of the oral dose of PF-05221304 was excreted unchanged in the urine indicating that renal clearance is not a major clearance mechanism for PF-05221304. 
1.3. Rationale for Study
The current study is the first trial specifically designed to evaluate the effect of 
PF-05221304 (compared to placebo) on liver fat, as assessed via magnetic resonance imaging proton density fat fraction (MRI-PDFF), and other pharmacodynamic/exploratory parameters in adults with NAFLD.  The investigational product will be administered orally, once-daily for up to 16 weeks. 
1.3.1. Rationale for Design
Along with an assessment of effect of PF-05221304 on liver fat, this study is designed to 
assess the safety and tolerability of a range of oral doses of PF-05221304 compared to 
placebo.  Eligible population is defined as having liver fat ≥8% as measured by MRI-PDFF 
at Screen 2 and
evidence of concomitant medical conditions, including features of metabolic 
syndrome, albeit stable with intent to stratify the population enrolled (refer to Section 1.3.2 andSection 4.3 for details).  While NAFLD is typically defined by liver fat 
≥5%, entry criteria at Screen 2 is proposed at ≥8% to account for a potential drift in liver fat 
during the run-in/stabilization period and negate the need for a randomization criteria related CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 21to liver fat assessment between Visit 4 (Day -14) and Visit 5 (Day 1; randomization).  A 
run-in period of ≥6-weeks post confirmation of eligibility and prior to randomization (ie, 
Visit 3 to Visit 5) is specifically included to permit stabilization of background/concomitant
medications and achievement of pre-randomization baseline. 
Overall, this study includes two distinct phases to confirm eligibility before subjects are 
progressed to Screen 2 to determine eligibility based on MRI-PDFF-assessed liver fat. As such, two separate informed consents will be obtained – 1
stlimited to pre-qualification visit 
only; and 2ndfor the main study only in those deemed to meet eligibility criteria based on 
pre-qualification procedures.  Between the pre- qualification visit and Visit 1 (Screen 1), 
many of the procedures and clinical laboratory tests assessed are identical – this is motivated by intent to confirm that the population progressed to Screen 2 is stable and consistently characterized in one of the two pre-specified 1
sttier stratification sub-populations of 
diagnosed/presumed NASH versus NAFLD with minimal inflammation and fibrosis.  As a measure of additional diligence and attempt to remove variability due to differences from laboratory-to-laboratory, the clinical laboratory tests assessed at pre-qualification and Visit 1 (Screen 1) are proposed to be analyzed by the sponsor-identified central laboratory.  
Furthermore, assessment of liver fat via ultrasound-based, but more quantitative FibroScan
®
and reported as controlled attenuation parameter (CAPTM) is included at pre-qualification and 
Visit 1 (Screen 1), in the entire study population, with a threshold of ≥280 decibels per meter 
(dB/m), is designed to help identify the likely eligible population based on MRI-PDFF via a 
more logistically feasible, and overall more efficient approach.    
 
 
  The use of generic abdominal ultrasound to detect liver fat is not 
advocated given the limited utility of this assessment for liver fat less than 20% although 
there is high specificity for detecting ≥20-30% liver steatosis.15
For the assessment of liver fat (either via FibroScan®or MRI-PDFF), subjects will be 
required to fast (water permitted) for ≥4-hours given the ability of food to impact the results.  
As an additional measure to limit variability, attempts will be made to standardize the 
nominal time, for FibroScan®assessment and, especially related to the primary endpoint 
(MRI-PDFF).  The clock time of day when these assessments are made should fall within a 
practical window ( ±2-hours) relative to clock time at Visit 1 (Screen 1) for FibroScan®and 
Visit 2 (Screen 2) for MRI-PDFF.  Serial assessments post randomization via MRI-PDFF and 
are planned to permit a mixed-model-repeated-measure analysis thereby allowing 
for evaluation of drug effect longitudinally and, at each visit, including end of dosing with the investigational product (IP) – ie, Visit 11 (Week 16). 
To date, the clinical experience with PF-05221304 is limited to a single Phase 1 trial in 
healthy subjects with repeated, in-patient/witnessed dosing up to 14-days.  Transitioning to the current study, with dominantly outpatient dosing in a patient population, increased variability in exposure and drug-response is plausible.  Hence, an added feature of the proposed study design is the frequent (every 2-week), outpatient visits during the first 8-weeks post randomization and monthly visits thereafter.  Furthermore, at least 1 interim analysis (IA) is planned [refer to Section 9.5 ] to permit ongoing review of safety of the 
population enrolled, amongst the planned activities. CCICCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 22Plasma exposure of PF-05221304 following a high-fat/high-caloric breakfast was similar 
relative to administration of PF-05221304 following an overnight fast – suggesting that investigational product can be administered without regard to food.  However, in this study, PF-05221304 administration will be requested to occur with the morning meal – given the importance of a morning meal to the standard-of-care diet counselling for the planned population.
Total duration of dosing of investigational product in this study is proposed as up to 
16 weeks .  This duration should permit an assessment of the primary pharmacology of PF-05221304 (ie, anti-steatosis), as well as potential improvement in liver function (as denoted by reduction in alanine transaminase (ALT) in the 1
sttier stratification comprising of 
subjects with diagnosed or presumed NASH – a sub-population selected to have elevatedALT at Visit 1 (Screen 1). 
A fixed, single-blind, 2-week baseline period (ie, Visit 4 to Visit 5) is included in this study 
with the explicit purpose of familiarizing the subjects with the dosing instructions for the blinded IP (refer to Table 3 ), and exclude subjects who are not
compliant with the blinded 
placebo prior to randomization in an attempt to minimize medications errors post randomization. 
1.3.2. Rationale for Population Enrolled 
NAFLD is a condition marked by excessive ( ≥5%) fat accumulation in the liver with a 
subgroup progressing to having hepatocellular injury and inflammation (ie, NASH), and 
cirrhosis, and a smaller proportion of patients developing hepatic cellular carcinoma (HCC).
7
In this study, while the entire study population will have evidence of liver fat ≥8% at 
Screen 2 and features of metabolic syndrome, the population enrolled will be stratified as denoted in Figure 1 as a means to permit an opportunity to evaluate potential for changes in 
measures of hepatic inflammation and fibrosis [refer to Figure 3 for additional detail 
regarding stratification]. CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 23Figure 1. Overview of C1171002 Study Population
Diagnosed or Presumed NASH
Biopsy-proven 
NASH in previous  
≤ 24-months•Features of Metabolic Syndrome* 
plus
•ALT > ULN & ≤ 5x ULN
and
•Liver stiffness on FibroScan® ≥ 7.0 kPa^
NAFLD with likely minimal inflammation & fibrosis
•Features of Metabolic Syndrome* 
plus
•ALT ≤ 1.25x ULN 
and
•Liver stiffness on FibroScan® < 7.0 kPa^Adult (≥18 and ≤ 70 yrs) patients with NAFLD defined as liver fat of ≥ 8%
Based on MRI-PDFF at Visit 2 / Screen 2 with No Additional Criteria at Randomization
*Defined by meeting ≥ 2 of 5 criteria related to fasting plasma 
glucose, fasting high-density cholesterol, fasting triglycerides, 
waist circumference, and blood pressure – refer to Section 4.1  
Plus , BMI ≥ 25 kg/m2(Western) or22.5 kg/m2(Asian)
In the 1sttier stratification, the two sub-populations will be categorized as having diagnosis 
or presumed NASH versus NAFLD with likely minimal inflammation and fibrosis.  Those with diagnosed/presumed NASH comprise of a subset with biopsy-proven diagnosis of NASH or
a constellation of clinical and liver imaging characteristics which are highly 
suggestive of a NASH diagnosis (in the absen ce of a liver biopsy).  The other sub-population 
of NAFLD with likely minimal inflammation and fibrosis will include those with alanine 
aminotransferase (ALT) ≤1.25x upper limit of reference range (ULN) for the 
sponsor-identified central laboratory, and no/minimal evidence of liver fibrosis (as measured 
by Vibration-Controlled Transient Elastography (VCTETM) and reported as liver stiffness 
measure (LSM, in kilopascals, kPa) using Fibroscan®and as such considered a distinct albeit 
related, population to those labeled as diagnosed/presumed NASH.  This NAFLD with likely minimal inflammation and fibrosis population is included in this Phase 2a, dose-ranging study, as it provides an opportunity to more broadly assess general safety (including potential mechanistic effect on platelet count and serum triglycerides) and additional potential metabolic benefits of ACC inhibition (such as improvement in glycemic control), than could be readily achieved via limiting the population to only subjects with NASH.  In addition, this study aims to permit those subjects within identified thresholds for ALT in combination
with 
liver stiffness in the F0 to F3 grades of fibrosis.  In doing so, population stratification acknowledges that elevated ALT alone is an imperfect marker of NASH and
the technology 
used (FibroScan®) to assess liver stiffness lacks the specificity to categorize F0-F2 grades of 
fibrosis with a great deal of precision.  Even with these caveats, the combination of these CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 24screening parameters may aide in characterizing the population in the absence of a liver 
biopsy – the current gold standard7despite its inherent limitations such as its invasive
assessment with procedural risks, potential for sampling errors, and inconsistency in interpretation of the histopathology. 
The liver stiffness cut-off for the sub-population categorized as presumed NASH was 
motivated by the intent to include those with F2-F3 grades of fibrosis though noted to permit likely F1 (but not F0) grades of fibrosis; similarly, the liver stiffness cut-off for the NAFLD with likely minimal inflammation and fibrosis reflects the intent to limit population to dominantly F1-F0 grades of fibrosis.  Considering that many patients diagnosed with NASH 
on liver biopsy have ALT ≤ULN, and many with elevated ALT do not have NASH on liver 
biopsy,
16it is acknowledged that the approach taken to stratify the study population is likely 
unable to definitively rule-out patients with NASH from the sub-population categorized as NAFLD with likely minimal inflammation and fibrosis. 
Beyond the categorization of the enrolled population into diagnosed/presumed NASH versus 
NAFLD with likely minimal inflammation and fibrosis, this study will apply a 2
ndtier 
stratification to identify the population with and without a diagnosis of type 2 diabetes mellitus (T2DM) based on glycated hemoglobin (HbA1C) result > 6.5% and/or current use ofagents for glycemic control ( Section 5.8.1 ).  This is to permit an assessment of whether 
PF-05221304 demonstrates insulin sensitization properties.  While PF-05221304 is not known to carry the potential risk of hypoglycemia, many of the agents used for the management of glycemic control in patients with T2DM carry this risk and hence a standardized approach to capture of such events will be undertaken – refer to Section 7.9.3.1.1 and Appendix 4 . 
Together, the study is designed to understand the effect of PF-05221304 on liver fat, ALT 
and other NASH-related biomarkers, glycemic parameters, fasting lipids, and effect on otherparameters [ie, Apolipoprotein A1, B (total), C3, E,  
  as well as assess effect of
PF-05221304 on metabolic parameters.  NASH-related markers include: cytokeratin18-M30 (CK18-M30) and CK18-M65, markers of apoptotic activity; 
 
ProC3, the N-terminal pro-peptide of type III 
procollagen which is a potential predictor of fast progressors and responders to therapy at baseline; and ProC6, the C-terminal fragment of α3 chain of procollagen type VI (also known 
as Endotrophin) which is a potential predictor of responders to insulin sensitizers at baseline.  
 
 
 
In this study, based on a combination of thorough medical history (including assessment of 
ethanol intake and administration of the Alcohol Use Disorders Identification Test (AUDIT) 10-item questionnaire, and clinical laboratory tests (including gamma glutamyl transferase [GGT] and percent carbohydrate deficient transferrin relative to total transferrin [%CDT]), CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 25medically-qualified site-staff will be required to rule-out alcohol-based as well as other 
causes of hepatic steatosis, and ensure that the population enrolled is confirmed, as best as possible, to have non-alcoholic fatty liver disease.
18These assessments (AUDIT and %CDT) 
are re-assessed prior to randomization and at end of dosing to confirm that while in the study alcohol intake remained in moderation.  Subjects with previously confirmed genetic polymorphisms, for example, patatin like phospholipase domain containing protein 3 (PNPLA3) carriers, are eligible given these polymorphisms are known to modify/increase risk for steatohepatitis but do not by themselves cause steatohepatitis. 
An explicit intent in this study is to exclude those with severe hepatic impairment 
(eg, ascites, hepatic encephalopathy, cirrhosis, and HCC) and severe renal impairment 
(ie, estimated glomerular filtration rate [eGFR] ≤30 mL/min) via specific eligibility criteria 
(refer to Section 4.1 andSection 4.2 ).  This is in line with: (1) the clinical data to date 
obtained in a trial enrolling healthy subjects with the current trial being the first in the patient population; (2) the mechanism of action (ie, primarily anti-steatotic) is unlikely to display anti-fibrotic action in a trial with up to 16 weeks of dosing; and (3) at present, lack of Phase 1 studies to describe the plasma PK of PF-05221304 in subjects with hepatic and/or renal impairment.   
 
 
 
 
 
 
 
 Thus, the inclusion/exclusion criteria have been defined to help 
limit pharmacokinetic variability while also capturing a population that is characteristic of the intended patient population. 
 
 
  In order to minimize PF-05221304 pharmacokinetic variability due to 
drug-drug interactions (DDIs), medications that have been shown to perpetrate OATP mediated clinically significant DDIs are excluded (notably gemfibrozil, cyclosporine).  Furthermore, concomitant use of potent inhibitors (eg, ketoconazole or itraconazole) or 
inducers (eg, rifampin) of CYP3A4/5 is to be avoided.   
  
 
 CCI
CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 26 
 
  Amongst the 
agents for glycemic control, thiazolidinediones (TZDs) and glucagon-like peptide-1 receptor (GLP-1r) agonists are not permitted given their potent anti-steatotic effect
18,19and hence the 
potential to confound the primary endpoint of this study.  Refer to Section 5.8 for complete 
details regarding permitted and excluded concomitant medications. 
Given the observed effects of PF-05221304 on platelet count, and serum triglycerides (both 
fasting and post-prandial) in the Phase 1 study (C1171001), in the current study, eligibility criteria for platelet count and fasting triglycerides is included (refer to Section 4 ) along with a 
monitoring strategy for each aspect – refer to Section 7.9.1 and Appendix 2 (platelet count), 
as well as Section 7.9.2 and Appendix 3 (fasting serum triglycerides). 
For the postulated improvement in insulin sensitivity with PF-05221304 administration in 
this study, diligence will be applied via monitoring of fasting plasma glucose (FPG), fasting plasma insulin (FPI), HOMA-IR, HbA1C, and in patients with T2DM the standardized capture of any hypoglycemic events (HAE s) along with hyperglycemia (refer to 
Section 7.9.3 ).  To ease subjects’ burden, at Visit 3 (Run-in), the sponsor will provide all 
eligible subjects with T2DM glucometer and associated ancillary supplies to permit at-home self-monitoring – at least once daily. 
Both females of childbearing potential as well as those who are of non-childbearing potential 
will be enrolled  
 
 
refer to Schedule of Activities (Table 1 and Table 2 ) as well as Section 4.4.6 and
Section 7.3.1 ].  Measures to prevent pregnancy in female partners of male subjects are
suggested to include a simple barrier method  
 
 
1.3.3. Rationale for Doses Selected 
In addition, to placebo, the PF-05221304 doses selected for this study (2, 10, 25 and 50 mg 
once daily) are based on the observed safety, tolerability, pharmacokinetic, and pharmacodynamic data from Study C1171001 in healthy adult subjects.  In Study C1171001, PF-05221304 was found to be well tolerated with an acceptable safety profile with single doses up to 240 mg and repeated doses up to 200 mg/day) administered and the MTD not
identified.  At the three highest doses ( ≥ 60 mg/day), a gradual decrease in platelet count, 
was observed with repeated doses over the 14 day dosing period, though none of the values met the criteria for thrombocytopenia.  In addition, a gradual increase in fasting andpost-prandial triglycerides was observed with repeated doses ≥40 mg/day with effect 
plateauing over the 14-day dosing period.CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 27Following repeated dosing in healthy adult subjects (Study C1171001), change from baseline 
in fructose-stimulated hepatic DNL was assessed via incorporation of deuterated water tracer into triglyceride-palmitate over a 10-hour period where fructose doses were given every 30-minutes to stimulate DNL.  Inhibition in DNL, a marker of target engagement, was 
observed in a dose and concentration-dependent manner with ≥90% DNL inhibition at 
PF-05221304 total daily doses ≥40 mg/day.   
 
 
 
 
  Given the projected degree of target engagement (ie, DNL inhibition) with 
the planned dosing frequency (ie, once-daily), PF-05221304 dosing frequency is proposed as once-daily (rather than Q12H evaluated on 5 of the 7 dose-levels in the Phase 1 Study C1171001 in healthy subjects).  The selected dose range spans a range of expected DNL inhibition, allowing for assessment of the relationship between DNL and the primary endpoint (liver fat), key secondary endpoint (ALT), as well as safety and other parameters.
 
 
 
  
 
 
 
 
 
 
The overall dose selection of PF-05221304 was also influenced by the aim to identify not 
only a minimally-effective dose but also characterize the dose-response using the tablet strengths available (1, 5, 25, and 50 mg – with the 2 lower strengths looking identical but different than the 2 higher strength tablets) as efficiently as possible.  As proposed, the dose-range planned will necessitate each subject to self-administer 3 tablets per day in order to maintain the double-blind design of this study. 
 
 
 CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 28 
  
 
 
1.4. Summary of Benefit Risk Assessment 
Study C1171002 is the first time that PF-05221304 is being administered to patients with 
NAFLD.  For the subjects participating in this study, close monitoring of their medical condition and safety, will occur as outlined in this protocol.  Those randomized to PF-05221304 may potentially derive benefit from reduction of DNL and its potential associated effects including reduction in hepatic steatosis, and potential reduction in liver inflammation.  Those randomized to placebo are not expected to obtain any specific benefit, beyond close monitoring of their medical condition and safety.  As of the issuance of this protocol, identified adverse drug reactions that may be encountered with the administration of PF-05221304 include elevation in blood triglycerides and reduction of platelet count.
Any adverse clinical impact of these findings are expected to depend on the severity of the 
potential reaction, and are minimized through – (1) the proposed frequent visits to site to permit close oversight of subjects’ safety via monitoring of a range of clinical assessments including laboratory tests, 12-lead ECGs, vitals, assessment of AEs; (2) inclusion of provisions for temporary discontinuation of dosing and permanent withdrawal from the study as outlined in Section 3.2 ; (3) institution of an Independent Review Committee (IRC) to 
undertake unblinded review of the safety data, while the study is on-going, and make recommendation(s) as to whether 1 or more doses should be paused/discontinued (refer to Section 3.3 andSection 9.5 ), amongst the planned activities.
2. STUDY OBJECTIVES AND ENDPOINTS
Primary Objective: Primary Endpoint:
To evaluate the dose-response for the effect on liver 
fat with a range of PF- 05221304 doses administered 
daily in adults with nonalcoholic fatty liver disease 
(entire study population)Percent change from baseline in liver fat, as assessed 
using MRI-PDFF, at Week 16
Secondary Objective(s): Secondary Endpoint(s):
To evaluate the dose-response for the effect on ALT 
with a range of PF- 05221304 doses ad ministered 
daily in the 1sttier stratification comprising of adults 
with diagnosed/presumed nonalcoholic 
steatohepatitis, onlyPercent change from baseline in ALT, at Week 16
To evaluate the safety and tolerability of a range of 
PF-05221304 doses administered daily in adults 
with nonalcoholic fatty liver disease (entire study 
population)Assessment of TEAEs, safety-related clinical 
laboratory tests, vital signs, and 12-lead ECGs CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 29Tertiary Objective(s): Tertiary Endpoint(s):
To evaluate the dose-response for the effect on liver 
fat, over time , with a range of PF-05221304 doses 
administered daily in adults with nonalcoholic fatty 
liver disease (entire study population)Percent change from baseline in liver fat, as assessed 
using MRI-PDFF, over time up to Week 16
To evaluate the dose-response for the effect on key liver function tests and NASH-related biomarkers 
over time , with a range of PF-05221304 doses 
administered daily in the 1
sttier stratification
comprising of adults with diagnosed/presumed 
nonalcoholic steatohepatitis, onlyPercent change from baseline, over time up to 
Week 16, for:
•ALT, AST, Alkaline Phosphatase, GGT
•CK18-M30 and CK18-M65
•Pro-C3 & Pro-C6
To evaluate the dose-response for the effect on other 
potentially mechanism-related parameters and 
metabolic parameters, over time , with a range of 
PF-05221304 doses administered daily in adults with nonalcoholic fatty liver disease (entire study 
population)Percent change from baseline, over time up to 
Week 16, for:
•Potentially mechanism-related parameters –
−Serum apolipoprotein A1, B (total), C3, E
•Metabolic parameters –
−HbA1C
−Fasting lipid panel (fasting total cholesterol, 
direct LDL-C, HDL-C, triglycerides, 
VLDL)
To evaluate the dose-response for the effect on glycemic parameters, over time , with a range of 
PF-05221304 doses administered daily in the 2
ndtier 
stratification comprising of adults with T2DM, onlyChange from baseline, over time up to Week 16, for:
•HbA1C
•FPG
•FPI
•HOMA-IRCCI
CCI
CCI
CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 30Tertiary Objective(s): Tertiary Endpoint(s):
For allendpoints, baseline defined as result closest prior to dosing at Visit 5 (Day 1); for list of terms corresponding to 
the abbreviations used herein, refer to Appendix 1 .
3. STUDY DESIGN
3.1. Study Overview
This is a randomized, double-blind, placebo-controlled, 5-arm (placebo, plus 4 active doses
of PF-05221304), parallel-group study.
Determination of eligibility for this study will occur via a sequential, 3-step process – starting 
with pre-qualification.  Subjects identified to be eligible based on pre-qualification will then undergo Visit 1 (Screen 1) with only those confirmed to continue to be eligible progressing to Visit 2 (Screen 2).  For a given sub ject, this 3-step eligibility assessment (from 
pre-qualification to Screen 2, inclusive) may take up to 2-months. 
Once confirmed to be eligible based on Screen 2 procedure(s), subjects will progress to a 
run-in phase when concomitant treatment(s) will be stabilized, and baseline-related visits will occur.  At Visit 5 (Day 1), subjects will be randomized to receive 1 of 5 blinded regimens for 
a duration of up to 16 weeks (ie, 108 ±4 days).  Excluding the pre-qualification visit, this 
study includes a total of 12 scheduled
outpatient visits in the morning ,  
 anda potential for up to at least 3 visits for repeat assessments (for 
procedures/tests at Visit 1, Visit 2, or 2ndFollow-up visit).  The total participation, from 
Visit 1 (Screen 1) to 2ndFollow-up visit, will be 27-weeks (minimum) to 35-weeks 
(maximum) – refer to Figure 2 . CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 31Figure 2.C1171002 Study Design
Baseline
(V4)
Day 1 = Randomization
(V5)
8-weeks and 14-weeksStabilize
background 
medications
Treatment with double -dummy, blinded medication 
(placebo, or1 of 4 doses PF-05221304)PBO
only
Screen 1 
(V1)
Screen 2 
(V2)
On-site FU (V12) 
[10±4 days post last dose]Day 14 
± 4
(V6)Day 28 
± 4
(V7)Day 42 
± 4
(V8)Day 56 
± 4
(V9)Day 108 
± 4
(V11)Continue re-stabilized background medications
[Telephone] Contact  FU 
[28&35days post last dose]Day 84 
± 4
(V10)Pre-Qualification Run-in 
(V3)Account for majority of placebo -
response related to increased 
compliance once in trial
Confirm subject can comply 
with IP dosing instructions 
prior to randomization 
(≥ 90 % compliance over 
14±2 day s)
Visits every  2 weeks up to V9
considering prior limited clinical experience Visit at Day 108 acknowledging dosing in 
16-wktox-was upto Day 112 plus intent to 
complete V11procedures while on IP
Each visit represents an outpatient visit to the site or Imaging facility and envisioned to last ≤ 2 -hours
Liver Imaging via MRI -PDFF expected at Screen 2 [eligibility for study; centrally read], Baseline between V4and V5 , plus V7, V10, V11
Assessment using FibroScan®to occur at pre -Qualification + Screen 1 andthen at Baseline between V4 and V5, plus V7, V10, V11
Ifat V9 platelet count is observed to be below lower limit of normal as reported by sponsor- identified central laboratory, additional 
(unplanned) visits should occur –refer to Appendix 26-weeks
At least 360subjects ( 72per arm) will be randomized at approximatel y 120sitesto ensure a 
minimum of 300subjects ( 60per arm) complete the study .  In each arm , 50% of subjects 
randomized will be deemed to be eligible for 1sttier stratification of diagnosed/presumed 
NASH ; with the remaining subjects per arm eligible for 1sttier stratification of NAFLD with 
likely  minimal inflammation and fibrosis –refer to Section 4.3.
Subjects who are noted to have non -evaluable baseline MRI -PDFF , as determined by  the 
sponsor -identified central imagi
ng vendor, may  be replaced, at sponsor discretion –refer to 
Section 7.1.4; otherwise, there are no plans to replace subjects who are prematurely  
withdrawn.  
To ensure th at the required minimum number of subjects complete the study, the 
plan is to overenroll b y approximate 20% to account for premature early withdrawal. 
3.2.Stopping Rule sfor Dosing in Individual Subjects
At investigator discretion, for subjects’ safety , dosin g with double -blinded investigational 
product (ie, post randomization), may  be stopped in an individual subject –either temporarily  
orpermanently .  In such cases, any  open TEAEs must be follo wed to resolution or until such 
time that the event is viewed t o have stabilized – refer to Section 8 for details –specificall y, 
Section 8.1 which outlines the requirements for reporting adv erse events, 
Section 8.2.3 detailing definition of serious adverse events, and Section 8.4.2 summarizing 
management of potentia l cases of drug- induced liver injury  which are categorized as 
potentially  important medical events.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 32An example where temporary discontinuation of dosing with investigational product , may  
be considered appropriate includes hospitalization with subsequent discharge within  7-days 
in stable medical condition , as determined b y medically -qualified investigator .  Of note, in 
this study ,re-challenge /re-initiation of dosing with double -
blinded investigational product 
should not be attempted in subjects who meet threshold for withdrawal based on platelet 
count ( Appendix 2) orfasting serum trigly cerides ( Appendix 3).
Examples where permanent discontinuation of dosing and withd rawal of the subject from 
the study  is deemed appropriate, as determined by investigators’ medical judgment, include:
Hospitalization due to serious adverse event (SAE) resulting in clinical 
decompensation of the subject andnecessitating continued inpatie nt stay  for more 
than 7- days;
Subjects observed to have a decline over time ultimately  reaching the threshold of 
< 75,000/ mm3in platelet count –refer to Section 7.9.1 and Appendix 2for additional 
guidance;
Individual subjects with consistently  increasing fasting serum trigly cerides over time 
ultimately  reaching the threshold of  800 mg/dL (9 mmol/L ) –refer to 
Section 7.9.2 and Appendix 3for additional guidance; 
Of note, in both the above cases of pre -identified laboratory  thresholds, 1 additional 
unplanned assessment may  be warranted be fore permanent withdrawal if the 
threshold is observed to be met as an isolated occurrence relative to all prior results 
andsubject is asy mptomatic.
3.3.Considerations for Pausing or Stopping Active Dose(s) Based on Observed Safety
The decision to pause orstop dosing at a study -level, for 1 or more active dose(s) of 
PF-05221304 may be considered based on recommendation from the Internal Review 
Committee (I RC) according to their review of unblinded, study -level emerging, observed
safet y data –refer to Section 9.5.
In addition , during study  conduct, after approximately  every 20% of the total planned 
randomizations [for example: 72 subjects (20%), 145 subjects (40%), 215 subjects (60%), 
and 290 subjects (81%) of planned 360 subjects], based on blinded safety  review by the 
selected members of the Sponsor’s study  team, unblinded review of the safety  data by  the 
IRC will be triggered and a determination of the safety  to continue the study documented if 
post randomization either of the below conditions are met –
More than 20% of subjects, develop a moderate or severe AE in the same system 
organ class (SOC) ;
More than 15 % of subjects meet the individual permanent discontinuation of dosing 
rules ( Section 3.2).

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 334.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
Subject eligibility  should be reviewed and documented by  an appropriate member of the 
investigator’s study
 team before subjects are included in the study .
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into 
the study :
1.Male or female subje cts between the ages of 18 (orthe minimum country -specific age of 
consent if > 18) and 70 years, inclusive ,at Visit 1 (Screen 1 ):
Male and female s ubjects of childbearing potential must agree to use highly  
effective method (s)of contraception [refer to Section 4.4.6] .  A subject is of 
childbearing potential if, in the opinion of the investigator, he/she is biologically  
capable of having children andis sexually  active.
Female subjects of chil dbearing potential must not be pregnant, breastfeeding, 
or planning to become pregnant for the duration of their participation in this 
study  and within 28 -days following last dose of blinded investigational 
product .
Female subjects of non -childbearing pote ntial must meet at least 1 of the 
following criteria:
a.Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or 
physiological cause; andhave a serum follicle -stimulating hormone (FSH) level
confirming the postmenopausal state, with a single repeat assessment, via the 
sponsor -identified central laboratory ,permitted to assess postmenopausal state , if 
needed ;
b.Have undergone a documented hy sterectomy  and/or bilateral oophorectomy; 
c.Have medi cally  confirmed ovarian failure;
All other female subjects (including female subjects with tubal ligations) are 
considered to be of childbearing potential .
At Pre -Qualification andVisit 1 (Screen 1 ), in all female subjects, serum
beta human chorionic gonadotropin ( -hCG )level, with a single repeat assessment, 
via the sponsor -identified central laboratory ,permitted to assess non-pregnant state, if 
needed .

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 342.At Pre -Qualification, pass the hula -hoop test [refer to Section 7.1.3] with a single repeat
assessment, permitted , if needed, to assess eligibility .
3.At Pre -Qualification, have an arm circumference compatible with the largest blood 
pressure cuff size available at individual sites 
[refer to Section 7.2.4] with a single repeat
assessment, permitted , if needed, to assess eligibility .
4.At Pre -Qualification andVisit 1 (Screen 1 ), total body  weight of > 50 kg (1 10 lbs) with
BMI  25kg/m2(for sites in Africa, Europe , North America ) orBMI22.5 kg/m2(for 
sites in Asia ), with a single repeat assessment of body  weight and/or BMI permitted to 
assess eligibility , if needed, at each of these 2 visits .
5.At Pre -Qualif ication andVisit 1 (Screen 1 ), meet the following criteria for liver fat , 
based on assessment via FibroScan, with a single repeat permitted to assess eligibility , if 
need ed, at each of these 2 visits:
CAPTM280dB/m ;
NOTE : if Pre -Qualification and Visi t 1values are discordant stratify ing a given 
subject , 1 more assessment via FibroScanon a separate day is permitted, with 2of 
the 4 assessments ( at least 1 between pre -qualification and repeat pre-qualification, 
plus at least 1 between Screen 1 and repeat Screen 1) required to meet above 
threshold before progressing to Screen 2.
6.At Pre -Qualification andVisit 1 (Screen 1 ), meet the following criteria, as assessed by  
sponsor -identified central laboratory ; with a single repeat on an y of these parameter s
permitted to assess eligibility , if needed, at each of these 2 visits:
International Normalized Ratio ( INR)1.3;
Albumin lower limit of normal ( LLN )
;
Platelet count 0.95x LLN ;
Fasting trigly cerides 400mg/dL  (4.5 mmol/L) ;
HbA1C  9.5%;
Fasting plas ma glucose 270mg/dL  (15.0 mmol/L);
Total bilirubin < 1.5x upper limit of normal ( ULN )anddirect bilirubin ULN .
NOTE: Subjects with a history  of Gilbert sy ndrome would be eligible for this 
study  provided direct bilirubin level is ULN plus ALT met cr iteria for 
applicable 1sttier stratification plus alkaline phosphatase, hemoglobin, and
reticulocy te count are all ULN.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 357.Documented liver biops y 24-months prior to Visit 1 (Screen 1 )with histological 
evidence of NASH in order to be classified in the s ub-population with biopsy -proven 
NASH , only .
8.In those without biopsy -proven NASH, only, at Pre-Qualification andVisit 1 (Screen 1 ), 
meet the following criteria for liver stiffness , based on assessment via FibroScan, with 
a single repeat permitted to asse ss eligibility , if needed, at each of these 2 visits :
LSM7.0kPa–
classified as presumed NASH;
LSM <
7.0kPa– classified as NAFLD with likel y minimal inflammation and 
fibrosis ;
NOTE : if Pre -Qualification and Visit 1 values are discordant in stratify ing a given 
subject , 1 more assessment via FibroScanon a separate day is permitted, with 2 of 
the 4 assessments (at least 1 between pre -qualification and repeat pre -qualification, 
plus at least 1 between Screen 1 and repeat Screen 1) required to meet above 
threshold before progressing to Screen 2.
9.In those without biopsy -proven NASH, only, at Pre-Qualification andVisit 1 (Screen 1 ), 
meet the followin g criteria, as assessed b y the sponsor -identified central laboratory , with 
a single repeat permitted to assess eligibility , if ne eded, at each of these 2 visits:
ALT > ULN and 
5x ULN – classified as presumed NASH;
ALT 1.25x ULN –
classified as NAFLD with likely  minimal inflammation and 
fibrosis ;
NOTE : if Pre -Qualification and Visit 1 values are discordant in stratify ing a given 
subject , 1more blood collection on a separate day is permitted, with 2 of the 
4assessments (at least 1 between pre -qualification and repeat pre -qualification, plus
at least 1 between Screen 1 and repeat Screen 1) required to meet above threshold 
before progressing to Screen 2.
10.In those without biopsy -proven NASH, only, at Pre-Qualification andVisit 1 (Screen 1 ), 
meet  2of the following 5 criteria for metabolic syndrome [for laboratory parameters , 
results must be as assessed by  the sponsor -identified central laboratory , with a single 
repeat permitted to assess eligibility , if needed, at each of these 2 visits ]:
FPG 100mg/dL (5.6 mmol/L) , oron pharmacological agents with explicit purpose
of improving glycemic control (refer to Section 5.8.1 foracceptable versus prohibited 
medications) ;
Fasting serum HDL -C < 40 mg/dL  (1mmol/L ) for males and < 50 mg/dL 
(1.3mmol/L ) for females, or on pharmacological agents with expl icit purpose to
increase HDL -C(refer to Section 5.8.2 foracceptable versus prohibited medications) ;

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 36Fasting serum trigly ceride ( TG)150 mg/dL (1.7 mmol/L) , oron pharmacological 
agents with explicit purpose to decrease TG(refer to Section 5.8.2 foracceptable 
versus prohibited medications);
Seated blood pressure ( BP)130/ 85mm Hg , oron pharmacological agents with 
explicit purpose for BP control (refer to Section 5.8.4 foracceptable versus prohibited 
medications) ;
Waist circumference 40inches (102 cm) for males and  35inches (89 cm) for 
females .
11.At Visit 2 ( Screen 2 ), liver fat of 8%, using MRI -PDFF acquisition protocol at the 
sponsor -qualified Imaging facility in close proximity  to the site , confirmed via a single 
repeat, if deemed necessary  by the 
sponsor -identified central imaging vendor of 
MRI -PDFF i mages – refer to Section 7.1.4.
12.At Pre -Qualification, e vidence of a personally  signed and dated informed consent 
document indicating that the subject has been informed of all pertinent aspects of the 
pre-qualification procedures of this protocol
.
NOTE : for subjects who qualify based on Pre -Qualifi cation procedures, at 
Visit 1 (Screen 1 ), evidence of a separate personally  signed and dated informed 
consent docume nt indicating that the subject hasbeen informed of all pertinent 
aspects of the main stud y, is required;
13.Subjects w illing and able to comply  with scheduled visits, treatment plan, laboratory  
tests, and other study -related procedures as outlined herein.
4.2.
Exclusion Criteria
Subjects with anyof the following characteristics/conditions will notbe included in the 
study :
1.Subjects with known prior participation (ie, randomized and received at least 1 dose of 
investigational product) in a trial involving PF-05221304.
2.Participation in other studie s involving investigational drug(s) within 30-days prior to 
Visit 1 (Screen 1 )andduring study  participation (ie, up to 2ndFollow -
up).
3.At Pre -Qualification andVisit 1 (Screen 1), history  of regular alcohol consumption 
exceeding 14drinks/week for female s or21drinks/week for males [1drink = 5 ounces 
(150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of h ard liquor)] 
within the previous 6 months.
4.At Pre -Qualification andVisit 1 (Screen 1), a total score of 8on the AUDIT 
questionnaire, indicating harmful or haz ardous ethanol consumption.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 375.At Pre -Qualification andVisit 1 (Screen 1), a positive ur ine drug test for illicit drugs.
6.At Pre -Qualification andVisit 1 (Screen 1), a persistent severe, uncontrolled 
hypertension; for example: se ated systolic blood pressure (SBP)180mm Hg and/or 
diastolic blood pressure (DBP)105mmHg after 5-minute of rest, with a single repeat 
permitted to assess eligibility , if needed, at each of these 2 visits :
For subjects with SBP 160mm Hg orDBP 100mm Hg, the Run -in Period must 
be used to refine the doses of the agents used for management of blood pressure (refer 
to Section 5.8.3 ) with the aim to have SBP 159mm Hg andDBP 99mm H g at
the time of randomization [refer to Section 4.3];
7.At Pre -Qualification andVisit 1 (Screen 1), asupine 12-lead ECG demonstrating 
QTc interval >450 msec ora QRS interval >120 msec:
If QT c interval exceeds 450 msec, or QRS interval exceeds 120 msec, the ECG 
should be repeated two more times and the average of the three QTc intervals or QRS 
intervals should be used to determine the subject’s eligibility .
8.At Pre -Qualification andVisit 1 (Screen 1), clinical evidence of hepatic decompensation, 
including, but not limited to esophageal varices, ascites or hepatic encephalopathy .
9. At Pre -Qualification andVisit 1 (Screen 1 ), evidence of other forms of chronic liver 
disease including but not limit ed to the entities listed below; evidence may include 
labora tory tests, as assessed by  the sponsor -identified central laboratory, with a single 
repeat permitted to assess eligibility , if needed, at each of these 2 visits :
Hepatitis B virus (HBV), defined b y presence of hepatitis B surface antigen (HBsAg);
Hepatitis C virus (HCV), defined b y presence of hepatitis C antibody (HCVAb) ;
irrespective of HCV RNA result (when reflexed based on a positive result for 
HCVAb) ;
Human Immunodeficiency  Virus (HIV) infecti on, defined as presence of HIV 
antibody ;
Known diagnosis of primary  biliary  cirrhosis, primary  sclerosing cholangitis, 
autoimmune hepatitis, or overlap s yndrome ;
Alcoholic liver disease , asevaluated via history  along with laboratory  tests including 
serum 
% carboh ydrate deficient transferrin result 1.5x UL N deemed to be highly  
suggestive to alcohol abuse ;
History  of genetic reason for fatt y liver; 
Wilson's disease, defined as ceruloplasmin level < LLN;

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 38Known diagnosis of hemochromatosis;
Alpha-1- antitry psin (A1AT) deficiency , defined as alpha - 1-antitry psin level < LLN; 
Prior known drug
-induced liver injury ;
Known or suspected Hepatocellular Carcinoma or other liver cancer;
History  of liver transplant, current placement on a liver transplant list, or curr ent 
model of end- stage liver disease (MELD) score >12;
Histological presence of cirrhosis on prior biops y.
10.At Pre -Qualification andVisit 1 (Screen 1), subjects with a n estimated glomerular 
filteration rate (eGFR) of < 30 mL/min using the Modification of D iet in Renal Disease 
(MDRD) equation, and serum creatinine (SCr) , as assessed b y the sponsor -identified 
central laboratory , with a single repeat permitted to assess eligibility , if needed, at each of 
these 2 visits .
11.At Pre -Qualification andVisit 1 (Screen 1), subjects with anyof the following medical 
conditions:
Any condition possibly  affecting drug absorption (eg, prior bariatric surgery , 
gastrectom y, ileal resection);
NOTE : subjects who have undergone cholecy stectomy  and/or appendectomy  are 
eligible for this study  so long as the surgery  occurred more than 6 months prior to 
Screen 1 ;
Diagnosis of ty pe 1 diabetes mellitus; 
In those with diagnosis of ty pe 2 diabetes mellitus, history  of:
Episodes of hy poglycemia of ‘severe’ intensity  either1in previous 1month or
3in previous 3 months;
Treatment with excluded agents for gl ycemic control – refer to Section 5.8.1 ;
Subjects with prior history  of pancreatitis;
Recent (ie, 
within the previous 6months) history  of congestive heart failure 
(New York Heart Association, NYHA ,class III or IV) or unstable angina;
A history  of m yocardial infarction, stroke ,ortransient ischemic attack ,in the 
previous 6 months;
  5% weight loss within the previous 3 months;

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 39Any malignancy  not considered cured (except basal cell carcinoma and squamous cell 
carcinoma of the skin); a subject is considered cured if there has been no evidence of 
cancer recurrence in the previous 5 years;
Active placement of medical devic es in/on thoracic cavit y –such as pacemakers, 
defibrillators [as these interfere with use of FibroScan].
12.Subjects meeting criteria for contraindication for MRI  –including the following:
History  of severe claustrophobia impacting ability  to perform MRI d uring the study  
even despite mild sedation/treatment with an anxioly tic;
Subjects with metal implants, devices, paramagnetic objects contained within the
body  and excessive or metal- containing tattoos;
Subjects unable to lie still within the environment of the MRI  scanner ormaintain a 
breath hold for the required period to acquire images even despite mild 
sedation/treatment with an anxioly tic;
13.At Pre -Qualification andVisit 1 (Screen 1), subjects on any  prohibited concomitant 
medication(s) orthose unwilli ng/unable to switch to permitted concomitant
medication(s) –refer to Section 5.8.
14.
Subjects with any  anatomical or pathological abnormality  that would either preclude or 
tend to confound the analy sis of study  data, including any  clinically  significant abnormal 
findings on MRI  obtained at Visit 2 (Screen 2 ), by the sponsor - identified central imaging 
vendor of MRI -PDFF images [refer to Section 7.1.4].
15.Male subjects with partners who are currentl y pregnant , pregnant female subjects ,
breastfeeding female subject s, as well as fertile male subjects and female subject s of 
childbearing potential who are unwi lling or unable to use highly  effective method sof 
contraception as outlined in Section 4.4.6 for the duration of the study  and for 
atleast 28days after the last dose of blinded investigational product .
16.
Blood donation (exc luding plasma donations) of approximately  1pint (500 mL) or more 
within 56 days prior to Visit 1 (Screen 1 )orduring the study  until Visit 12 (on-site 
Follow -up).
17.Investigator site staff members directl y involved in the conduct of the study and their 
family members, site staff members otherwise supervised by  the investigator, or subjects 
who are Pfizer emplo yees, including their family  members, directl y involved in the 
conduct of the stud y
.
18.At Pre -Qualification andVisit 1 (Screen 1), other acute or chron ic medical or psy chiatric 
condition including recent (within the past y ear) or active suicidal ideation or behavior or 
laboratory  abnormality  that may  increase the risk associated with study  participation or 
investigational product administration or may  interfere with the interpretation of study  
results and, in the judgment of the investigator, would make the subject inappropriate for 
entry  into this study .

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 404.3. Randomization Criteria
At Pre -Qualification , following completion of informed consent, subjects will be 
assigned a single 8 -digit study -specific subject identification (SSI D) number by  the 
IRT (interactive response technology ) system 
which will be retained throughout the 
duration of participation in the study ;
At Visit 5 (Day 1 ), IRT will be used to assig n each eligible subject a randomization 
number, with this number recorded on the electronic Case Report Form (e -CRF) .
A computer -generated randomization code using the method of random permuted 
blocks will be utilized to randomize subjects 1:1:1:1:1 (acros s placebo or 1 of 
4active doses of PF -05221304) at Visit 5 (Day 1) prior to the first dose of the 
double -
blinded investigational product (PF-05221304 or matching placebo)
provided subjects’ satisfy allthe following criteria:
Eligibility  criteria outlined in Section 4.1 and Section 4.2;
A negative urine drug test for illicit drugs for sample collected at 
Visit 4(Day -14) and results as reported b y sponsor -identified central 
laboratory ;
Fasting (8 hours overnight, with water permitted) serum triglyceride result 
of 400mg/dL  (4.5 mmol/L ), for sample collected at Visit 4 (Day  -14), as 
reported b y sponsor -identified central labora tory; 
In females, 
serum pregnancy  test at Visit 4 (Day  -14) as reported b y 
sponsor -identified central laboratory  and urine pregnancy  test on-site(in 
females of childbearing potential) at Visit 5(Day  1) as reported on- site using 
supplies offered b y spons or-identified central laboratory , are negative for 
pregnancy  –refer to Section 7.3.1;
Noted to be 
90% compliant (based on pill count) with the single -blind 
placebo administered from Visit 4 (Day  -14) to 1 day before Visit 5 (Day  1), 
inclusive, for a total duration of 142days;
Total score of < 8 on the AUDIT questionnaire, as assessed at Visit 5 ( Day 1).
Study  will employ  2-tier stratification as outlined in Figure 3.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 41Figure 3. Two-Tiered Stratification in Study C1171002
Entire Study Population 
Adult (≥18 and ≤ 70 yrs) patients with NAFLD defined as liver fat of ≥ 8%
1stTier Stratification*
2ndTier StratificationDiagnosed or
Presumed NASHNAFLD with 
likely minimal inflammation and fibrosis
T2DM^ Non-T2DM Non-T2DM
*Across planned total sample size, aim to randomize ≥ 50% in diagnosed/presumed NASH and ≤50% in NAFLD
^Those with T2DM across 1sttier stratification to  be pooled for purposes  of objectives/endpoints related to this sub-populationT2DM^
Via randomization, an attempt will be made to balance the number of subjects assigned to 
receive each active dose of PF-05221304 and placebo within the 1sttier stratification.  
However, an imbalance in the number of subjects assigned to receive each active dose of PF-05221304 versus placebo between the two-tiered stratification is allowed. 
4.4. Lifestyle Requirements
After
confirmation of eligibility at Visit 2 (Screen 2), andstarting at Visit 3 (Run-in), 
subjects will be instructed to maintain the guidelines described below for the duration of participation in the study.  These guidelines must be reiterated at Visit 5 (Day 1).
4.4.1. Dietary Restrictions 
•Subjects must abstain from all food and drink (except water) for 
≥8-hours prior to 
any blood sample collections for clinical laboratory tests, fasting glucose monitoring, 
•Water may be consumed as desired (ad libitum);
•Blinded investigational product must be administered every day with the morning 
meal;
•On scheduled outpatient visits to the site, in the morning , from Visit 4 (Day -14) 
through Visit 11 (Week 16), subjects must be instructed to arrive without having 
morning meal/breakfast, self-administration of the blinded investigational product, and
morning dose of concomitant medication for the control of glycemia, 
dyslipidemia, and BP, if applicable, for the given day;CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 42•At Visit 4 (Day -14) through Visit 11 (Week 16), inclusive, the morning meal will 
be consumed with above mentioned medications at the site [with the meal either
provided by the site orthe subject provided a voucher (or similar) by the site to 
purchase the meal before arriving to the site for each visit];
•Subjects will be counseled on appropriate dietary and lifestyle guidelines, at 
Visit 3 (Run-in) and re-iterated at Visit 5 (Day 1):
•Subjects will be asked to maintain these guidelines throughout participation in the 
study (ie, Visit 12, the on-site Follow-up);
•Counseling on dietary guidelines should be individualized in accordance with 
local medical standards of care for these patients and appropriate for the concomitant medical condition(s) of each subject.
4.4.2. Alcohol, Caffeine, and Tobacco
•Intake of alcohol is permitted in moderation [refer to Exclusion Criterion 3for limits 
on amount of alcohol consumption];
•Consumption of caffeinated drinks and nicotine-containing products is permitted 
during participation in the study; however, there may be a need for brief interruption 
while at the site and/or Imaging facility, depending on local policy.
4.4.3. Activity
•Subjects will not
be permitted to engage in physically strenuous exercise (for 
example: heavy lifting, weight training, calisthenics, and aerobics) within 48-hours
before each blood sample collection for clinical laboratory tests for the duration of participation in the study; physical activity at an individual subject’s normal pace ispermitted.
4.4.4. Confinement to Site 
•Each outpatient visit to the site will occur with the subject arriving at the site
between 
approximately 6 AM and 10 AM with each visit envisioned to last ≤2-hours;
•Visit to the Imaging facility for MRI-PDFF [ ±FibroScan®] assessment will have 
restrictions related to prior meals/food consumption and clock time of day [refer to 
Schedule of Activities (Table 1 ) and Section 7.1 ].CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 434.4.5. Confinement at Imaging facility
•Each outpatient visit to the Imaging facility (for MRI-PDFF) will occur following a 
fast (water permitted) of ≥4-hours and same time of day ( ±2 hours) relative to 
MRI-PDFF completed at Visit 2 (Screen 2); refer to Section 7.1 for additional details; 
•Visits to Imaging facility can occur on the same day as the visit to the site either
prior orafter the Site visit;
•Visit to Imaging facility is also permitted to be on days separate from visits to 
site; but in this case must still occur within the pre-defined visit window [refer to 
Schedule of Activities (Table 1 )].
•For assessment via FibroScan®, visits will occur either to the site orthe Imaging 
facility – depending on where the FibroScan®device is located – however, the
location of the device must be kept consistent at individual sites throughout the study execution;
•Similar to MRI-PDFF, each assessment via FibroScan
®to occur following a fast 
(water permitted) of ≥4-hours and same time of day ( ±2 hours) relative to 
FibroScan®assessment completed at Visit 1 (Screen 1).
4.4.6. Contraception
In this study, male subjects who are able to father children, and female subjects who are of 
childbearing potential have an 80% chance of being randomized to receive PF-05221304; 
 
Female subjects who, in the opinion of the investigator are sexually active and at risk for 
pregnancy must agree to use highly effective contraception throughout the study and continue use for at least 28 days after the last dose of blinded investigational product.  The 
investigator or his or her designee, in consultation with the subject, will confirm that the subject has selected the appropriate method of contraception for the individual subject from the list of permitted contraception methods below and instruct the subject in their consistentand correct use.  At time points indicated in the Schedule of Activities (Table 1 ), the 
investigator or designee will inform the female subject of the need to use the highly effectivemethod of contraception consistently and correctly and document such conversation, and the subject’s affirmation, in the subject’s chart.
Highly effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently and correctly (ie, perfect use).  One
of the below options must be used to satisfy the requirement for highly effective 
contraception in female subjects participating in this study:
1. Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, inserted, injected, implanted; and including oral, as well as transdermalCCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 44methods unless prohibited by  local regulations or ethics committee decision ),
combined with either :
a.Male orfemale co ndom;
b.Male sterilization.
2.Correctl y placed copper -containing intrauterine device (IUD ) or intrauteri ne sy stem 
combined with either :
a.Male orfemale condom;
b.Male sterilization.
3.Male sterilization with absence of sperm in the postvasectomy  ejaculate in the fe male 
subjects’ partner combined w ith either :
a.Male orfemale condom;
b.Bilateral tubal ligation/bilateral salpingectom y or bilateral tubal occlusive 
procedures.
4.Bilateral tubal ligation/bilateral salpingectom y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label)
combined with one of the following:
a.IUD orintrauterine s ystem;
b.Male orfemale condom ;
c.Male sterilization.
All sexually active male subjects must agree to prevent potential transfer t o and exposure of 
female partner(s) to drug through ejaculate by  using a condom consistently  and correctl y, 
beginning with the first dose of double -blinded investigational product at Visit 5 (Day  1) and 
continuing for at least 28 days after the last dose o f blinded investigational product.
In female subjects ,
pregnancy  testing will be performed a t time points indicated in the 
Schedule of Activities (Table 2).  The specif ic contraceptive method ( s)in the females of 
childbearing potential will be documented ,and at every visit their consistent and correct use 
will be ascertained and documented in the subject’s source document .  For additional details, 
refer to Section 7.3.1 .
In addition , the investigator or designee will instruct all subjects of childbearing potential to 
call immediately  if the selected contraception method is discontinued or if pregnancy  is 
known or suspected in the female subject ormale subject s’female partner.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 454.5.Sponsor ’sQualified Medical Personnel
The contact information for the sponsor 's appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located inthestudy  portal.
To facilitate ac cess to appropriatel y qualified -medical personnel on study -related medical 
questions or problems, subjects are provided with a contact card. The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigat orsite, and contact details for a contact center in the 
event that the investigat orsite staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .The contact number can also be used by  investiga tor
staff if they  are seeking advice on medical questions or problems; however, it should be used
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available. It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team f or 
advice on medical questions or problems that may arise during the stud y.The contact 
number is not intended for use by the subject directly, and if a subject calls that number, he 
or she will be directed back to the investigator site.
5.STUDY TREATMENTS
For the purposes of this study , and per International Conference on Harmoni s ation ( ICH)
guidelines, investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference /comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33).
For this study , the investigational products are tablets for oral administrati on in the following 
strengths:
1mg PF-05221304;
5mg PF
-05221304;
25mg PF
-05221304;
50mg PF
-05221304;
Placebo matching PF -
05221304 tablet strengths of 1 mgand 5mg;
Placebo matching PF -05221304 tablet strengths of 25 mg and 50 mg.
Note that the drug substance is denoted as PF- 05221304 -82.  All descriptions using this term 
are equivalent to PF-05221304 for the purpose of identify ing the active moiety  releva nt to 
this study .  An investigational product manual will be provided to the sites prior to the 
initiation of randomization of subjects into the study .

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 465.1.Allocation to Treatment
In this stud y, at least 360 subjects will be randomized to receive 1 of the regi mens described 
in Table 3.  Each dose will consist of 3tablets (1 tablet f romeach of the 3 bottles dispensed). 
Table 3. Randomized Regimens in Study C1171002
Regim enRegim en Description
(dosed once -daily)Number of PF -05221304 tabletsNumber of 
PF
-05221304 -matching 
placebo tablets
1mg 5mg 25mg 50mg 1/ 5mg 25/ 50mg
A Placebo - - - - 2 1
B PF-05221304 – 2mg 2 - - - - 1
C PF-05221304 –10mg - 2 - - - 1
D PF-05221304 –25mg - - 1 - 2 -
E PF- 05221304 –50mg - - - 1 2 -
Allocation of subjects to dosing regimens will occur through the use of an interactive 
response technology  (IRT) system ( interactive Web- based response [IWR]).  The site 
personnel (stud y coordinator or specified designee) will be required to enter or select 
information including but not limited to the user’s identification ( ID)and password, 
the 
protocol number ,andthe subject number. The IRT system will provide a confirmation report 
containing the subject number , random ization number ,and container number (s)assigned.
The confirmation report must be stored in the site’s files.
The study -specific I RT reference manual will provide the contact information and further 
details on the use of the IRT system . 
5.2.Breaking the Bl ind
The study  will be subject and investigator blinded.
At the initiation of the study , the 
investigator site will be instructed on the method for 
breaking the blind.  The method will be an electronic process .  Blinding codes should be 
broken only in excep tional circumstances when knowledge of the actual treatment code is 
absolutely  essential for further management of the subject. Investigators are encouraged to 
discuss with a member of the study  team if they  believe that unblinding is necessary . When 
theblinding code is broken, the reason must be fully  documented and entered on the case 
report form (CRF) .
5.3.Subject Compliance
The number of pills returned by  the subjects at Visit 5 (Day  1), Visit 7 (Week 4), 
Visit 9(Week 8), Visit 10 (Week 12), and Visit 1 1(Week 16) will be used to assess subject 
compliance.  Compliance (as assessed b y pill count) will be defined as self -administration, 
by the subjects, of:

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 47  90% compliance with pills in each bottle of the study -supplied blinded placebo 
administered from Visit 4 (Day  -14) to 1day prior to Visit 5 (Day  1), inclusive ;
  80% compliance with pills in each bottle for the double -blinded IPfrom 
Visit 5(Day  1)to Visit 11 (Week 16), inclusive; investigators must closely follow 
non-compliant , randomized subjects in order to enhance their adherence to IP;
Post randomization , at each dispensation visit [refer to Schedule of Activities
(Table 1)], subjects who are < 80% compliant must be re -educated on the 
importance of daily  administration of investigational product, as much as 
possible; with the overall aim to maintain 80% compliance over the 16 -
week 
duration of dosing. 
5.4. Investigational Product Supplies
5.4.1. Dosage Form(s) and Packaging
Blinded investigational p roduct s (PF -05221304 and its matched placebo )will be provided as 
tablets for oral administration.  The 1 -mg, 5 -mg, 25 -mg, and 50 -mg strength tablets of 
PF-05221304 and matching placebo tablets will be supplied in separate bot tles and labeled 
according to local regulatory  requirements. 
PF-05221304 / matching -placebo for dispensation at the visits denoted in the Schedule of 
Activities (Table 1)will be packaged with each bottle containing a sufficient number of 
tablets to permit dosing for 14 (+2) day sduring single -blind period from Visit 4 (Day -14) to 
1day prior to Visit 5 (Day 1)or28(+4) day s from Visit 5 (Day 1)andonwards . 
5.4.2. Prepara tion and Dispensing
The investigational product will be dispensed using an IRT drug management sy stem from
Visit 4(Day  -14) to Visit 10(Week 12) at selected visits [refer to Schedule of Activities –
Table 1]. A qualified staff member will dispense the investigational product via unique 
container numbers in the 
bottles provided, in quantities appropriate for the study  visit 
schedule. Subject sshould be instructed to m aintain the IP in the bottle (s)provided 
throughout the course of dosing at the labelled storage conditions and return with the 
dispensed 
bottle sto the site at each visit starting at Visit 5 (Day  1) and through 
Visit 11(Week 16) .  The instructions for dosing will be provided to the sites and individual 
subjects (refer to Section 5.5).  The number of bottles dispensed and the number of tablets
administered per dose will be identical for all ra ndomized regimens.
5.5.Administration
Subjects will be 
instructed to take the blinded investigational product at the sam e time of day  
with the morning meal each day .  In addition, subjects will b e instructed to delay  the 
self-administration of the blinded inve stigational product as well as their medications for 
glycemic control, dyslipidemia, and BPcontrol, if applicable, on the day s of their outpatient 
visit to the site; on these day s, these medications w ill be administered at the site with the 
morning meal –refer to Section 4.4.1. 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 48Subjects will swallow the investigational product whole, and will not manipulate or chew the 
investigational product 
prior to swallowing .
Subjects will be provided dosing instructions at Visit 4 (Day  -14) to aide in remembering the 
correct steps to self -administer blinded investigational product.
5.6. Investigational Product Storage 
The investigator oran approved representative ( eg, pharmacist, study  coordinator )will 
ensure that all investigational products
are stored in a secured area with controlled access 
under required storage conditions and in accordance with applicable regulatory  requirements.
Investigational product sshould be stored in their original container sand in accordance with 
the label s. 
Any storage conditions stated in the SRSD willbe superseded b y the storage conditions 
stated on the product label.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated ,and/or room -temperature products).  This should 
be captured from the time of investigational product receipt throughout the study .  Even for 
conti nuous- monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions should be available .  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability  to store or view the minimum/maximum 
temperature for all non
-working day s upon return to normal operations.  The operation of the 
temperature monitoring device and storage unit (for example, r efrigerator), as applicable, 
should be regularl y inspected to ensure they are maintained in working order. 
Any excursions from the product label storage conditions should be reported to Pfizer upon 
discovery . The site should actively pursue options for r eturning the product to the storage 
conditions described in the labeling , as soon as possible.  Deviations from the storage 
requirements, including any  actions taken, must be documented and reported to Pfizer . 
Once an excursion is identified, the investig ational product must be quarantined and not used 
until Pfizer provides permission to use the investigational product.  It will not be considered a 
protocol deviation if Pfizer approves the use of the investigational product after the 
temperature excursion. Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site prior to the initiation of Visit 4 (Day  -14) in 
this study .
Site staff will instruct subjects on the proper storage requirements for take home 
investigational products
.  The site staff should refer to the Investigational Product Manual for 
additional guidance on storage conditions and actions to be taken when conditions are 
outside of the specified range. 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 495.7. Investigational Product Accountability 
The investiga torsite must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.   All investigational products will be 
accounted for using a drug accountabilit y form/record.
All bottles of blinded investigational product must be returned to the investigator by  the 
subject at every  dispensation visit and at the end of the study [refer to Schedule of 
Activities –Table 1].
5.7.1. Destruction of Investigational Product 
Supplies 
At the end of the study, the sponsor or designee will provide guidance on the destruct ion of 
unused investigational product (eg, at the site). If destruction is authorized to take place at 
the investigator site, the investigator must ensure that the materials are destroy ed in 
compliance with applicable environmental regulations, institutio nal policy , and any  special 
instructions provided by  Pfizer ,and all destruction must be adequatel y documented.
5.8.Concomitant Treatment(s)
Given the duration of the dos ing phase in this study (ie, up to 16 weeks), whenever possible , 
attempts must be made to notalter the doses and regimens of the background /concomitant
medic ations after randomization [ie, Visit 5 (Day 1)], and until Visit 12 (on-site Follow -up). 
All concomitant medications taken during the study must be recorded with, at a minimum, 
the indic ation for use.  In addition, for diabetes, lipid -modify ing, BP control medications, 
daily  dose, and start and stop dates of administration must also be captured.  All subjects 
must be questioned about concomitant medication at each outpatient visit. 
Medic ations taken within 6-weeks before Visit 5 (Day 1)will be documented as a prior 
medication.  Medications taken after dosing of double -blind I P at Visit 5 (Day  1) and until 
the 2ndFollow -up visit (or telephone contact) will be documented as concomitant 
medications.
5.8.1. Medications for Glycemic Control
The use of the following class esof agents is not permitted within 8-weeks prior to Visit 
1 (Screen 1 )and until Visit 12 (on-site F ollow -up):
TZDs such as pioglitazone and rosiglitazone;
Subcutaneously  administered agents for gl ycemic control (eg, insulin, exenatide, 
liraglutide, pramlintide).

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 50Subjects are permitted to be on stable doses of up to a maximum of 3 oral agents for 
glycemic control ,starting at  8-weeks prior to Visit 1 (Screen 1) and until Visit 12 (on-site 
Follow -up), across the country -specific ,approved classes of agents including (but not limited 
to) the following:
Biguanide such as metformin; 
Sulphony lureas such as acetohexamide, chlorpropamide, tolazamide, tolbutamine, 
glimepiride, glipizide, glyburide;
Meglitinide analogues s uch as repaglinide, nateglinide;
Dipeptidy l peptidase
-IV inhibitors (DPP- IVi) such as sitagliptin, sax agliptin, 
vildagliptin;
  -glucosidase inhibit ors such as acar bose, miglitol;
Sodium -glucose cotransporter 2 inhibitors such as canagliflozin, dapagliflozin, 
empagliflozin.
5.8.2. Lipid -modifying medications 
The use of monoclonal antibodies inhibiting p roprotein c onvertase subtilisin/kexin 
type 9 (PCSK9 )such as alirocumab, evolocumab is notpermitted within 12-weeks prior to 
Visit 1(Screen 1) and until Visit 12 (on-site Follow-up). 
Subjects are permitted to be on stable doses of up to a maximum of 3 lipid-modifying 
agents, starting at 8-weeks prior to Visit 1 (Screen 1 ) and until Visit 12 (on-site 
Follow -up), across the count ry-specific, approved classes of agents including (but not limited 
to) the following –
Statins such as atorvastatin, simvastatin, rosuvastatin, pravastatin;
Bile acid sequestrants such as cholest yramine, colestipol;
Fenofibrate , a f ibric ac id derivative;
Nicotinic acid / niacin ;
Ezetimibe ;
Doses and agent(s) are permitted to be adjusted at Visit 3 (Run- in), with stable doses 
for 6-weeks before Visit 5(Day  1) required for continuing participation in this 
study .

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 51The use of the following selected agents i s notpermitted starting at Visit 3 (Run -in)
and until Visit 12 (on-site Follow- up):
Gemfibrozil (a potent OATP inhibitor);
Colesevalam. 
Subjects on either of the above two oral agents , at Visit 3 (Run -in), must be 
willing to switch to other acceptable ag ents and on stable doses of the 
acceptable agents for 6-weeks before Visit 5(Day  1) in order to participate 
in this study .
5.8.3. Medications for Controlling Blood Pressure 
Across the man y classes of agents for management of hy pertension, 
subjects are permitt ed to 
be on stable doses of up to a maximum of 3 agents ,starting at 8-weeks prior to Visit 
1 (Screen 1) and until Visit 12 (on-site F ollow -up), across the country - specific, approved 
classes of agents ; 
Starting at Visit 3 (Run-in), doses of medications (and additional medications can be 
added to a maximum of 3) in order to control BP and meet criteria needed to progress 
to randomization [refer to Section 4.2, Exclusion C riterion 6].
5.8.4. Other Acceptable Concomitant Medications
Any subject on the following list of medications must be on stable doses [ ie,  8-weeks 
prior to Visit 1 (Screen 1 )and until Visit 12 (on-site Follow -
up), where possible ]:
Non-steroidal anti -inflammatory  medications (NSAIDs) such as ibuprofen, 
ketoprofen, diclofenac, naproxen, indomethacin, meloxicam; and celecoxib; 
Also permitted is intermittent use of acetaminophen/paracetamol at doses of 
up to 1 gram per day andintermittent use of NSAIDs ( for example : for 
short -term pain management) ;
Inhaled and topical corticosteroids:
NOTE : Intercurrent treatment with sy stemic steroids, during participation in 
the study , may  be permitted if treatmen t does/will not exceed 14 -days;
Thyroid replacement therapy , as well as acceptable contraception medication and 
hormone replacement therap y (in eligible female subjects), etc;
Anti- psychotic medications such as olanzapine, risperidone;
Antidepressant medications such as tricy clic agents, selecti ve serotonin reuptake 
inhibitors, and serotonin/norepinephrine reuptake inhibitors;

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 52•Vitamin E, including high doses so long as regimen is stable ;
•Certain herbal supplements but only following consultation with sponsor.
5.8.5. Prohibited Medications 
Across the agents used for glycemic control, lipid-modification, and BP control, certain 
medications are notpermitted – refer above to Section 5.8.1 toSection 5.8.3 .
Also, use of drugs historically associated with fatty liver are prohibited within any≥≥4-week
interval in the previous 12 months prior to Visit 1 (Screen 1) –
•Examples include: amiodarone, methotrexate, systemic glucocorticoids (such as 
prednisone, dexamethasone, triamcinolone, budesonide, betamethasone), 
anabolic steroids, tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone replacement, valproic acid, other known hepatotoxins;
In addition
, subjects using the following medications within 8-weeks prior to 
Visit 1 (Screen 1) orneeding them at any time until Visit 12 (on-site Follow-up) should not
participate in this study –
•Chronic use of immunosuppressants such as cyclosporine and tacrolimus;
•Pharmacological agents with approved indication for weight loss such as orlistat and 
sibutramine; 
•Over-the-counter appetite- simulant or appetite- suppressant, as advertised; 
•(Medical-grade) marijuana, regardless of medical indication;
•Specific classes of agents given current study is 1ststudy in patient population –
•Coumadin-type anticoagulants orother anticoagulants (eg, dabigatran); 
though aspirin at doses ≤ 325 mg/day is permitted
•Anticonvulsants – specifically when prescribed for the explicit management 
of seizures (though use of some agents for other indications may be permitted; 
for example : use of benzodiazepines for management of anxiety);
•Antiarrhythmics – specifically those agents whose primary mechanism of 
action is sodium or potassium channel blockade (eg, procainamide, phenytoin, 
quinidine, propafenone; as well as amiodarone, dofetilide, sotalol);
•NOTE:β-adrenergic receptor blocking agents (eg, atenolol, metoprolol) 
and calcium channel blockers (eg, diltiazem, amlodipine, nifedipine) are permitted;
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 53•Use of chronic agents which are clinically significant OATP inhibitors (eg, 
cyclosporine, gemfibrozil, rifampin).
5.9. Rescue Medication
There is no rescue therapy to reverse any adverse events (AEs) observed with administration 
of investigational product; standard medical supportive care must be provided to manage the AEs including administration of carbohydrates to treat hypoglycemic events.
Subjects with T2DM
with repeated fasting glucose values > 270 mg/dL (15.0 mmol/L), as 
reported by the sponsor-identified central laboratory orself-checking conducted by subjects 
via sponsor-provided glucometers, must be withdrawn.
6. STUDY PROCEDURES
Prior to the conduct of any study-specific procedures – at the Pre-Qualification Visit and 
separately at Visit 1 (Screen 1) – each subject must provide informed consent.
•Request for the subjects to arrive at the site following an overnight fast of ≥ 8-hours 
for either the Pre-Qualification orScreen 1 visit will notbe considered 
study-specific; such instruction is classified as routine standard-of-care for the targeted population for this study. 
6.1. Proposed Chronology of Procedures 
For the procedures described below, where multiple procedures are scheduled at the same 
timepoint(s) relative to dosing, the following chronology of events should be adhered to, where possible
:
•12-lead ECG: obtain prior to vital signs assessment, blood samples, and prior to 
dosing [refer to Section 7.2.3 ];
•Vital Signs (blood pressure, pulse rate) : obtain after 12-lead ECG collection but prior 
to obtaining blood samples and prior to dosing [refer to Section 7.2.4 ];
•Fasting blood samples [for safety ( Section 7.3 ),  
after assessment of 
12-lead ECG and vital signs but prior to dosing;CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 54•Other pre-dose procedures : should be obtained/performed as close as possible to the 
scheduled time, but may be obtained before or after blood specimen collection;
•Dosing : must occur with the morning meal; and where applicable, after any predose 
blood sample collection(s).
6.2. Pre-Qualification
Refer to the Schedule of Activities (Table 1 and Table 2 ) for the study procedures to be 
completed at the pre-qualification visit.  Subjects can only proceed to Visit 1 (Screen 1) of the main study when deemed to meet eligibility criteria [refer to Section 4.1 and Section 4.2 ] 
for the selected procedures completed as part of pre-qualification. 
6.3. Screening (Visits 1 and 2)
Refer to the Schedule of Activities (Table 1 and Table 2 ) for the study procedures to be 
completed at the 1
stand 2ndScreening visits.  The two screening visits are to be performed 
sequentially . 
•At Visit 1 (Screen 1), all screening procedures except assessment of liver fat by 
MRI-PDFF, will be undertaken to determine eligibility – refer to Section 4.1 and
Section 4.2 ;  
•Only after subjects are identified to be otherwise eligible, should they proceed with 
the Visit 2 (Screen 2) to the Imaging facility to undergo liver fat assessment via 
MRI-PDFF acquisition to assess whether they meet Inclusion Criterion # 11.
Subjects will be screened within 8-weeks (minimum) and14-weeks (maximum) prior to
the first dose of the blinded investigational product to confirm that they meet the subject selection criteria for the study.  The investigator (or an appropriate delegate at the investigator site) will obtain informed consent from each subject. 
In rare
cases, subjects may be re-screened; however, this is permitted only when, due to 
logistical constraints , the maximum period between Visit 1 to Visit 5 (ie, Screen 1 to Day 1),
of 14 weeks, is exceeded.  In such cases, all pre-screening andscreening procedures must be 
repeated and the subject assigned a new 8-digit SSID number.  Subjects must be deemed to meet all the eligibility criteria including assessment of liver fat via MRI-PDFF at Screen 2 visit, under the new 8-digit SSID.
To prepare for study participation, subjects will be instructed on the Lifestyle Requirements 
(Section 4.4 ) and Concomitant Treatments ( Section 5.8 ).CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 556.4. Visit 3 (Run -in)through to Visit 11 ( Week 16) 
Refer to the Schedule of Activities (Table 1and Table 2) for the study  procedures to be 
completed starting at Visit 3
(Run- in) through Visit 11 (Week 16). 
6.5.Follow -up Visit
In this stud y, there are twoFollow -up visits –
1stis an on -site visit where the subjects will return to the site 10 4days post last 
dose of blinded investigational product – Visit 12;
2ndis a telephone contact visit (unless local regulations dictate on- site visit) to occur
28-to 35-days, inclus ive, following the last dose of blinded investigational 
product
NOTE : this visit can be considered as on- sitein order to permit follow -up of open 
TEAEs and/or abnormal laboratory  tests from prior visit(s) , as needed.
Refer to the Schedule of Activities (Table 1and Table 2) for the study  procedures to 
be completed at each of the two Follow -up visits.
6.6.Subject Withdrawal / Early Termination
Subjects may  withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the dis cretion of the investigator or sponsor for safety  (refer to 
Section 8.1.3) or behavioral reason s, or the inability  of the subject to comply  with the 
protocol -required schedule of study  visits or p
rocedures at a given stud y site. 
In this study ,any subject who discontinues participation in the trial post the pre -qualification 
visit (eg, viewed as in eligible based on procedures completed), ordiscontinues based on 
Screen 1 or Screen 2 procedures (ie, Screen Fail) will have no additional procedures 
completed.  However, an early termination visit is to be considered for all subjects who 
were randomized andreceived at least 1dose of the investigational product, and then are 
prematur ely withdrawn from the study.  Subjects should return to the sitefor final safety  
assessments to be scheduled as early as practically feasible following the decision to 
with draw but 14-days after last dose of blinded investigational product.   Subjects 
should be questioned regarding their reason for withdrawal.  
At the earl y withdrawal visit, 
every  effort must be made to complete the assessments outlined in the Schedule of Activities
(Table 1and Table 2).  Lack of completion of all or any  of the earl y termination procedures 
will not be viewed as p rotocol deviations so long as the subject’s safety  was preserved.
Withdrawal of consent :
Subjects who request to discontinue receipt of study  treatment will remain in the study  and 
must continue to be followed for protocol specified follow
-up procedures. The only  
exception to this is when a subject specificall y withdraws consent for an y further contact 
with him or her or persons previously  authorized by  the subject to provide this information.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 56Subjects should notify  the investigator in writing of the deci sion to withdraw consent from 
future follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by  the investigator, as to whether the withdrawal is only from 
further receipt of investigational product or also from study  procedures and/or posttreatment 
study  follow -up, and entered on the appropriate CRF page. In the event that vital status 
(whether the subject is alive or dead) is being measured, publicly  available information 
should be used to determine v ital status only  as appropriatel y directed in accordance with 
local law.
Lost to 
follow -up: 
All reasonable efforts must be made to locate subjects to determine and report their ongoing
status. This includes follow- up with persons authorized by  the subjec t as noted above. Lost 
tofollow -up is defined by  the inabilit y to reach the subject after a minimum of 2documented 
phone calls, faxes, or e -mails as well as lack of response b y the subject to 1registered mail 
letter. All attempts should be documented in the subject’s medical records. If it is 
determined that the subject has died, the site will use locally  permissible methods to obtain 
the date and cause of death. If the investigator’s use of a third -party representative to assist 
in the follow -up por tion of the study  has been included in the subject’s informed consent, 
then the investigator may use a sponsor -retained third -party representative to assist site staff 
with obtaining the subject’s contact information or other public vital status data neces sary to 
complete the follow -up portion of the study . The site staff and representative will consult 
publicly  available sources, such as public health registries and databases, in order to obtain 
updated contact information. If, after all attempts, the subject remains lost to follow- up, then 
the last -known- alive date as determined by  the investigator should be reported and 
documented in the subject’s medical records.
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subjec t.  All attempts to contact the subject and information received during contact attempts 
must be documented in the subject’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The investi gator should inquire 
about the reason for withdrawal, request that the subject return all unused investigational 
product(s), request that the subject return for a final visit, if applicable, and follow up with 
the subject regarding an y unresolved adverse e vents ( AEs).
If the subject withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additi onal data should be 
collected.  The sponsor may retain and continue to use any  data collected before such 
withdrawal of consent.
Subjects withdraw nfrom the study , after receiving at least 1 dose of the 
double -blinded I P 
(ie, after dosing at Visit 5 [Day  1]), will notbe replaced –except those with non -evalua ble 
baseline MRI -PDFF ass essment –refer to Section 7.1.4 . 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 577.ASSESSMENTS
Every  effort should be made to ensure that the protocol -required tests and procedures are 
completed as described. However ,it is anticipated tha t from time to time there may  be 
circumstances outside of the control of the investigator that may  make it unfeasible to 
perform the test. In these cases the investigator will take all steps necessar y to ensure the 
safet y and well -being of the subject. W hen a protocol -required test cannot be performed ,the 
investigator will document the reason for this and any corrective and preventive actions that 
heor she has taken to ensure that normal processes are adhered to as soon as possible. The 
study  team will be informed of these incidents in a timely  manner .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the st udy.
7.1.Liver 
Assessments using FibroScanand MRI -PDFF
7.1.1. Background on Liver Assessment Techniques
FibroScanis an ultrasound based technique permitting an assessment of liver fat (via 
controlled attenuation parameter -CAPTM) and liver stiffness (via vibration controlled 
transient elastograph y - VCTETMand reported as liver stiffness measure – LSM), developed 
by EchoSens.   These measurements are performed on the right lobe of the liver through 
intercostal spaces with the subject ly ing in dorsal decubitus with the right arm in maximal 
abduction.  A transducer probe delivers a painless, mechanical impulse to the liver and 
measures the resulting shear wave.   The LSMis directl y proportional to the velocity of the 
shear wave.
  Simultaneously , the CAPTMmeasures th e ultrasonic attenuation coefficient in 
the forward and return path of the radio -frequency  pulse through the liver.  To account for 
varying subcutaneous fat lay ers, the device is equipped with at least two probes ; the 
M+probe for lean/overweight adult subjects ,and the XL+ probe for overweight /obese 
adults.  After a total of 10 valid, serial measures are acquired per assessment , the device 
calculates the median L SM and CAPTMvalues and reports these values simultaneously .
MRI -PDFF technique further improve d upon the conventional Dixon in -and out -of-phase 
(IOP) method to give a quantitative, standardized, and objective MRI measurement of fat 
content.  MRI -PDFF utilizes a gradient echo sequence with low flip angle (FA) to minimize 
T1bias, corrects T 2* decay (due to iron overload) via modeling of the fat signal as a 
superposition of multiple frequency  components from five different lipid types, and is 
applied in each of the 9 Couinaud segments.  This technique improves fat quantification 
accuracy  for the enti re liver permitting quantification of small differences/changes following 
pharmacological intervention.  Relative to the reference standard of magnetic resonance
spectroscop y (MRS), MRI -PDFF has the advantages of permitting fat mapping for the entire 
liver via an imaging -based technique versus a biochemical -based technique that provides 
data on liver fat content in a small region of interest in the liver. 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 587.1.2. Assessment of Liver Fat and Stiffness –using FibroScan
In this stud y, assessment of liver fat and liver stiffness using FibroScanwill occur at 
scheduled visits outlined in the Schedule of Activities (Table 1)and Section 4.4.5.  The 
results for liver fat (via CAPTM)in decibels per meter (dB/m) and liver stiffness (via LSM) in 
kilopascals (kPa) to determine whether an individual subject qualifies at pre -qualification to 
progress to Screen 1 (or at Screen 1to progress to Screen 2) will be display edon the 
FibroScandevice at 
the end of each assessment.  These results do notneed independent 
over-read but steps to ensure that acquisition was complete and accurate are required –per 
training to be offered to atleast 2site staff (who must be sonographers or comparable ) by 
EchoSens , and certified as operators based on this training by  EchoSens, at the start of the 
study .  As much as practically possible , attempts will be made to ensure each individual 
subje cts’ assessment is performed b y the same site staff.
Each acquisition will require the subjects to be in a supine position with the right arm placed 
flat above the head and will take approximatel y 10 minutes.  Each assessment must be 
undertake nfollowing a fast (except wa
ter) of ≥ 4- hours, and as much as practically 
possible , at the same time ( 2-hours) of the day relative to assessment at Visit 1 (Screen 1) . 
Complete details regarding acquisition
susing FibroScanto assess CAPTMand L SM will be 
offered b y EchoSens before the initiation of pre -qualification portion of this study .  All 
images acquired must be saved b y the site until the conclusion of the study ; the summary  of 
numerical results (including quality -related outputs) must be printed and saved by the site 
(orImaging facility , as applicable) as part of each subject’s source documents. 
7.1.3. Assessment of Liver Fat Using MRI- PDFF Acquisition and Analysis
In this stud y, at scheduled visits [refer to the Schedule of Activitie s(Table 1)and 
Section 4.4.5] liver fat will be assessed via MRI, using the PDFF acquisition protocol.  In 
order to ensure that the population ident ified for this trial can be appropriately
 imaged via an 
MRI  machine, at the pre-qualification visit , subjects will undergo a hula -hoop test –
Subject will be asked to be in the standing position with arms either to the side or
verticall y up above the head , feet positioned close together, and weight evenly  
distributed across both feet;
NOTE: as much as practically  possible, the same position of the arms must be 
used for all MRI -PDFF assessments in this trial ;
Using a sponsor -approved hula -hoop, an attempt w ill be made to slide the hoop over 
the subjects head and determine if the hoop can pass over the subjects’ trunk and 
hips;
Hula
-hoop will be passed while the subject is at the end of a normal expiration (when 
lungs are at their residual capacity ); 
Ifthe hula -hoop slides easily  from the head down to the feet, the subject is eligible 
and confirmed to fit inside the site -specific MRI machine and its respective bore size;

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 59Ifthe hula- hoop cannot slide down to the feet (eg, fits snug at the waist or hips), the
subject is deemed ineligible for this study ;
Additional details on steps for
identification of the appropriate hula-hoop 
circumference, which depends on the individual Imaging facility’s MRI machine 
opening (ie, bore diameter) along with bed thickness, and coils selected, will be 
provided in an Imaging Manual offered to the sites prior to the start of the study . 
Transportation of the subjects to the I maging facility does notneed to be supervised b y the 
sitestaff.  Each assessment will require the subjec ts to be in a supine position in the confined
space of the MRI scanner for approximatel y 25 minutes with the image acquisition 
undertake nfollowing a fast (except water) of ≥ 4-hours, and as much as practically 
possible , at the same time ( 2-hours) of the day relative to assessment at Visit 2(Screen 2) . 
Across the sites selected for this study , the sponsor -identified central imaging vendor will 
train the staff at the Imaging facility on the MRI -PDFF acquisition protocol, onjust-in-time 
review of the acquired images for assessment of images being deemed evaluable, and on 
transfer (preferabl y electronically) of the images to the sponsor -identified central imaging 
vendor for anal ysis and quantification of liver fat.  Only the staff members at the Imaging 
site who are trained by the sponsor -identified central imaging vendor are permitted to 
acquire images in the subjects who consent for this s tudy ; in rare/limited situations, 
exceptions may be grante d with written approval of the sponsor .  Complete details on the 
MRI -PDFF acquisition protocol, determination of quality  of images, and transmission of data 
to sponsor -identified central imaging ven dor will be provided in an Imaging Manual offered 
to the sites prior to the start of the stud y.
As much as practically possible , analy sis of the MRI -PDFF images acquired from baseline 
(ie, between Visit 4 and Visit 5) 
to Visit 11 (Week 16) will be undertak en by  a single 
colleague at the sponsor -identified central imaging vendor who will be blinded to individual 
subjects’ clinical data, a s well as randomization and stratification assignment .  However, this 
colleague will be unblinded to Visit of each assessm ent (ie, Screen 2, Baseline, etc). 
7.1.4. Analysis of MRI -PDFF Images Including Determination of Eligibility 
Subjects’ eligibility  for this study  based on liver fat as assessed via MRI -PDFF at 
Screen 2will be made by the sponsor -identified central imaging vend or, only.  The individual 
subjects’ liver fat result will notbe communicated to the site [though results from 
Screen 2and Baseline may be known to the sponsor ].  In the case of the Screen 2 MRI, sites 
will only be informed whether the subjects meet eligi bility  criteria orif the screening MRI 
should be repeated once –as determined b y the sponsor -identified central imaging vendor.  
For all subsequently  scheduled MRI -PDFF assessments, sites will only be informed whether 
the images are deemed evaluable (or not); of note, subjects with non- evaluable baseline 
images [as determined by  the sponsor -identified central imaging vendor ]may be withdrawn 
and replaced, a t the discretion of the sponsor . 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 60Management of incidental findings 
An incidental finding is one unknown to the subject that has potential health or reproductive 
importance, which is discovered unexpectedly in the course of a research study, but is unrelated to the purpose and beyond the aims of the study.
The MR images
will be reviewed by the sponsor-identified central imaging vendor. The 
purpose of this review is to evaluate images for the amount of fat in the liver. Central image review is not a complete medical review of the subject. If, during the central review process, an unexpected observation is identified and this finding could, in the opinion of the central reviewer, have a significant health or reproductive consequence, this finding may be shared with the study sponsor for disclosure to the principal investigator. All follow-up testing andfinal diagnosis will be left to the discretion of the medical professionals at the site or those with an existing physician-patient relationship. The principal investigator will be responsible for reporting any AEs identified from incidental findings as described in the Adverse Event 
Reporting section. Identification of such incidental findings during the central review 
process should not be expected, and the site maintains responsibility for performing a general safety review of all images as per site protocols. 
7.2. Safety-Related Assessments
7.2.1. Physical Examination
In this study, physical examinations are to be performed at nominal time points specified in 
the Schedule of Activities (Table 1 ). 
Physical examinations may be conducted by a physician, trained physician's assistant, or 
nurse practitioner as acceptable according to local regulation.  A full physical examination
will include head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.  A targeted physical 
examination specifically covering visual examination of skin, examination of the eyes using 
an ophthalmoscope, as well as auscultation of the pulmonary system, will be conducted at Visit 6 (Week 2), Visit 9 (Week 8) and Visit 11 (Week 16).  In addition
, this targeted 
physical examination will be incorporated into the full physical examinations prior to the first dose of the investigational product.  The brief physical examination will be focused on 
general appearance, the respiratory and cardiovascular systems, as well as towards subject reported symptoms.CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 617.2.1.1. Measurement of Waist Circumference
Waist circumference will be measured at the nominal time points specified in the Schedule of 
Activities (Table 1) using a flexible anthropometric tape and ideally , reporting the 
measurement in centimeters with accuracy  to the nearest 0.1 centimeter (or 1/16thinch) .  
Measurement will be undertaken as follows:
Either before or after the assessment of bod y weight;
While subject is in a standing position with arms resting comfortabl y at the side;
Under standard conditions including post
-void, with the tape touching the skin (not 
clothing);
At the end of a normal expiration (when lungs are at their residual capacity ).
And the measurement will consider the following anat omical features as benchmarks:
Circumference of the narrowest part of the torso as viewed f rom the anterior aspect 
or;
If the narrowest part of the torso cannot be identified, the measurement must be made 
of the smallest horizontal circumference in the area between the ribs and the iliac 
crest.
7.2.2. Body Weight
In this stud y, assessment of body weigh t will occur at the nominal time points specified in 
the Schedule of Activities (Table 1) per the following specifications –
Weight will be recorded using a scale placed on a stable, flat surface in a 
(semi) -private area;
Same scale, as much as practically possible , will be used with the scale reporting 
weight in kilograms or pounds , and accuracy  to the nearest 0.1 kg[or0.2pounds]
-ie, the device used for this stud y must be able to distinguish a differe nce between 
68.4 kg and 68.3 kg.
Measurement must be undertaken:
At approximatel y the same time of the day at each nominal time point;
After the subject has been asked to void (ie, forced void);
Under standard conditi ons (eg, subjects must wear light clothing with content of 
their pockets emptied orhospital gown and notbe wearing shoes or bulky lay ers 
of clothing/jackets);

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 62With subjects remaining still while on the weighing scale.
7.2.3. 12- lead Electrocardiogram
In this st udy, assessment of cardiac conduction via 12
-lead ECGs will occur at the nominal 
time points specified in the Schedule of Activities (Table 1) per the following specifications:
All scheduled 12-lead ECGs should be performed after the subject has rested quietly  
for 10-minutes in a supine position ;
Single supine 12- lead ECGs will be obtained ; the ECG collected at Visit 5(Day  1) 
will serve as each subject’s baseline;  
Refer to Section 6.1 for proposed chronolog y of procedures for nominal time points 
when 12 -lead ECG assessments coincide with other procedures.
In some cases, it may
 be appropriate to repeat abnormal 12 -lead E CGs to rule out improper 
lead placement as contributing to the ECG abnormality .  It is important that leads are placed 
in the same positions each time in order to achieve precise ECG recordings.  If a 
machine -read QTc value is prolonged, as defined above, repeat measurements may  not be 
necessary  if a qualified phy sician’s interpretation determines that the QTc values are in the 
acceptable range.
7.2.4. Blood Pressure and Pulse Rate
In this stud y, assessment of vital signs (including seated blood pressure, and puls e rate) will 
occur at the nominal time points specified in the Schedule of Activities (Table 1)per the 
following specifications –
At the pre
-qualification visit , the s ubjects’ arm circumference [eg, using a flexible 
anthropometric tape] should be measured at the midpoint of the length of the upper 
arm and the appropriate cuff selected andused throughout the study  to measure 
BP/pulse rate via an automated device using a n oscillometric method ( not
auscultation):
Subjects with arm circumference greater than the largest cuff size available at 
each site are not eligible.
Single seated blood pressure/pulse rate will be measured with the subject’s arm 
supported at the level of the heart, and recorded to the nearest mm Hg, following a 
rest of  5-minutes ; the assessment at Visit 5(Day  1) will serve as each subject’s 
baseline ;
Same arm (preferabl y the dominant arm) will be used for blood pressure/pulse rate 
assessment throughout the study ;

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 63Blood pressure /pulse rate assessment should not be taken from the arm with an 
intravenous catheter, if placed;
Subjects should be instructed nottospeak during blood pressure/pulse rate 
measurements;
Refer to Section 6.1 for proposed chronolog y of procedures for nominal time points 
when vital sign assessments coincide with other procedures.
Additional collection times, or changes to collect ion times of blood pressure / pulse rate wi ll 
be permitted, as necessary , to ensure appropriate collection of safet y data.
7.3.
Clinical Laboratory Tests
Theblood/urine samples for the clinical laboratory tests [summarized in Table 4] related to 
safet y and expl oratory  biomarkers 
will be collected at the nominal time points specified in 
the Schedule of Activities (Table 2). 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 64Table 4. All Planned Safety-Related Laboratory Tests and Exploratory Biomarkers 
in Study C1171002
Hematology Chemistry Urinalysis Other
−Hemoglobin
−Hematocrit
−RBC count
−Reticulocyte count 
(Abs)
−MCV
−MCH
−MCHC
−Platelet count
−WBC count
−Total neutrophils 
(Abs)
−Eosinophils (Abs)
−Monocytes (Abs)
−Basophils (Abs)
−Lymphocytes (Abs)−BUN
−Creatinine [ andeGFR using 
MDRD]
−Plasma glucose (fasting)
−Calcium
−Sodium
−Potassium
−Chloride
−Total CO 2(Bicarbonate)
−AST (SGOT)
−ALT (SGPT)
−Alkaline phosphatase
−GGT
−Total Bilirubin
−Direct (conjugated) bilirubina
−Indirect (unconjugated) 
bilirubina
−Total bile acids
−Creatine Kinaseb
−Uric acid
−Albumin
−Total protein−pH
−Glucose (qual)
−Protein (qual)
−Blood (qual)
−Ketones
−Nitrites
−Leukocyte 
esterase
−Urobilinogen
−Urine bilirubin
−Microscopyc−Plasma aPTT, PT, INR
−Serum FSHd
−Serum and urine 
pregnancy test [refer to
Section 7.3.1 ]
−Urine drug teste
−Serologyf: HBsAg, 
HBcAb, HCVAb (and if positive, reflex HCV RNA), HIV
−α1-antitrypsin
f
−Ceruloplasminf
−Serum % carbohydrate 
deficient transferrinf
−HbA1Cg
−Fasting Lipid Panelh
Additional exploratory biomarker 
assessmentsiinclude:
−Serum apolipoproteins A1, B(total), C3, E
−Plasma Insulin (fasting)  
−Calculate HOMA-IR using fasting glucose & 
insulin
−CK18-M30, CK18-M65
−ProC3 & ProC6Additional Tests (Needed for instances of suspected Hy’s law)
−AST, ALT
−Total bilirubin
−Albumin
−Alkaline phosphatase
−Direct bilirubin
−Indirect bilirubin
−Creatine kinase
−GGT
−PT/INR
−Total bile acids
−Acetaminophen drug levels and/or protein adduct level
a. Direct + indirect bilirubin measured at Pre-qualification, Screen 1, V4, and V5; after initiation of investigational 
product, direct + indirect bilirubin measured only when total bilirubin is >ULN
b. Test to be assessed at Pre-qualification, Screen 1, V4, and V5; after initiation of investigational product, this test 
measured only when ALT or AST is >ULN
c. Only if urine dipstick is positive for blood, protein, nitrites or leukocyte esterase
d. At Pre-qualification, Screen 1, ONLY; and in females, only
e. At Pre-qualification, Screen 1, V4, ONLY; minimum requirement for urine drug test include cocaine, 
tetrahydrocannabinol (THC), opiates/opioids, benzodiazepines and amphetamines
f. At Pre-qualification, Screen 1, ONLY [ in addition , %CDT also assessed at V4, V5, andV11]
g. HbA1C = glycosylated hemoglobin (NGSP certified method)
h. Includes total cholesterol, triglycerides, VLDL, HDL-C, and direct LDL-C
i. As part of clinical laboratory tests collected at V4 though V11, only – refer to Table 2
For list of terms corresponding to the abbreviations used herein, refer to Appendix 1
•Allblood samples for scheduled clinical laboratory tests must be obtained following 
an overnight fast (except water) of ≥≥8-hours . CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 65Additional laboratory results may be reported on these samples as a result of the method of 
analysis orthe type of analyzer used by the sponsor-identified central laboratory or 
secondary laboratory; oras derived from calculated values.  These additional tests would not
require additional collection of blood. 
Unscheduled clinical laboratory tests for subject safety may be obtained at any time during 
the study to assess any perceived safety concerns and shipped to the sponsor-identified central laboratory for analysis.
Additional
details regarding sample collection, processing, and shipment will be offered in 
the study-specific central laboratory manual to be provided prior to the start of the study.
7.3.1. Pregnancy Testing
All pregnancy tests (serum andurine) used in this study must have a sensitivity of 
at least 25 mIU/mL, and must be performed using supplied offered by the sponsor-identified 
central laboratory certified laboratory. 
For female subjects of childbearing potential , following a negative pregnancy test result 
andafter confirmed eligibility based on Visit 2 (Screen 2) tests(s), appropriate contraception 
must be commenced and the second negative pregnancy test result will then be required prior to randomization.  In addition
, at a minimum , 2 negative serum pregnancy tests (ie, negative 
pregnancy test at Visit 1 and Visit 4) plus a negative urine at Visit 4 (Day -14) and Visit 
5 (Day 1; randomization) are required before receiving double-blind IP – starting on Day 1.  In the absence of regular menstrual bleeding, the female subject should have used highly effective method of contraception (refer to Section 4.4.6 ) for at least 28-days before 
Visit 4 (Day -14).
Pregnancy tests will be performed at times defined in the Schedule of Activities (Table 2 ) to 
confirm that the subject has not become pregnant during the study.  Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active treatment period (ie, Day 1 through Week 16, inclusive) and when potential pregnancy is otherwise suspected, and may be repeated if requested by institutional review boards (IRBs)/ethics committees (ECs)or if required by local regulations.  In the case of a positive confirmed pregnancy, the subject will be withdrawn from administration of investigational product and from the study.
7.4. Rater Qualifications
In this study, the AUDIT questionnaire will be completed by the site staff based on responses 
offered by the subjects – at the visits outlined in the Schedule of Activities (Table 1 ).  
Training for the site staff completing this questionnaire will be offered by the sponsor as part of the protocol-specific training ahead of the initiation of the study. 
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 667.6. Exploratory Biomarkers
Blood samples for exploratory biomarkers – including NASH-related biomarkers, potential 
mechanism-related parameters, metabolic parameters, and exploratory markers of liver function – will be collected at the nominal time points defined in the Schedule of Activities
(Table 2 ).  Refer to list of endpoints outlined in Section 2 that encompass these exploratory 
biomarkers.
•These samples must be processed and shipped as indicated in the study-specific 
laboratory manual provided to the investigator site, prior to initiation of study, to 
maintain sample integrity:CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 67•Any deviations from the sample handling procedure (eg, sample collection and 
processing steps, interim storage or shipping conditions), including any actions 
taken, must be documented and reported to the sponsor. On a case-by-case basis,
the sponsor may make a determination as to whether sample integrity has been compromised.  Any deviation from the specified sample handling procedure resulting in compromised sample integrity will be considered a protocol deviation;
•Any scheduled
collection prior to next dose of blinded investigational product, if 
undertaken post dose, will be captured as a protocol deviation even if results are 
deemed evaluable;
•Refer to Section 6.1 for proposed chronology of procedures for nominal time points 
when these collections coincide with other procedures;
•Samples will be analyzed using a validated analytical method (which need notmeet 
Good Laboratory Practice (GLP) standards, especially for these exploratory
endpoints) but in all cases, the method will be in compliance with Pfizer standard operating procedures.
CCICCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 687.8. Blood Volume
In this study, the total blood sampling volume for individual subjects will be approximately 
400 mL .  This includes approximately 40 mL blood drawn across the clinical laboratory tests 
at the pre-Qualification; and the remaining approximately 360 mL blood drawn from Visit 
1 (Screen 1) through the On-site Follow-up visit, inclusive. CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 69Additional blood samples may be taken for safety assessments , only , provided the total 
volume taken during the study  does not exceed 550 mL.
7.9.Specific Subject Safety Scenarios
7.9.1. Pote ntial Cases of Thrombocytopenia
While thrombocy topenia (defined as platelet count below 100,000/mm3) has notbeen 
observed in the completed Study  C1171001, in the current study , platelet count as reported
by the sponsor -identified central laboratory , with or without any  accompany ing 
signs/sy mptoms, will be assessed versus the threshold outlined in Appendix 2every  two 
weeks post randomization (on Day  1/ Visit 5) up to Visit 9 (Week 8) and monthly  thereafter 
(Visit 10 / Week 12 and Visit 11 / Week 16).
In subjects observed to have platelet count below the LLN at Visit 9 (Week 8), unplanned 
visits at Week 10 and Week 14 (in addition to the scheduled Visit 10[Week 12] and 
Visit 11[Week 16]) should be used to –
Inquire about adverse events via open -ended inquiry ; 
Andcollect blood sample to permit safety- related laboratory  assessments included 
hematology  panel assessment by  the sponsor- identified central laboratory .
Subjects observed to have a decline over time u ltimately  reaching the threshold of 
<75,000/mm3in platelet count as outlined in Appendix 2should be withdrawn with the 
primary  reason for withdrawal ca ptured as an adverse event of thrombocy topenia . 
7.9.2. Potential Cases of Hyper triglyceridemia
In Study  C1171001, gradual increases in fasting and post -prandial serum trigly cerides have 
been observed –refer to Section 1.2.2.  Hence, in the current study, fasting serum 
trigly cerides as reported by  the 
sponsor -identified central laboratory , with or without any  
accompan ying signs/sy mptoms, will be assessed versus the threshold outlined in Appendix 3. 
Individual subjects with consistently  increa sing fasting serum trigly cerides over time 
ultimately  reaching the threshold of  800 mg/dL (9 mmol/L ) as outlined in 
Appendix 3should be withdrawn with have the primary  reason for withdrawal ca ptured as an 
adverse event of hypertrigly ceridemia .
7.9.3. Management of Glycemic Control in Patients with T2DM
Events of hy pogly cemia ( HAE )and fasting plasma glucose will be routinely  monitored 
during participation in the study , in subjects with T2DM.  At Visit 3/ Run -in, subjects will 
be gi ven the following instructions/guidance to be complied with for the duration of 
participation in the study :
Subjects will beprovided the following (as provided to the sites by  the sponsor ).
To aide in management of their T2DM the following (or similar) it ems:

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 70Home glucose m onitoring supplies including a sponsor -provided, 
plasma -referenced, home glucometer and accompany ing supplies ;
Diary to be completed at home for an y symptomatic episodes and brought to each
visit to the site along with the glucometers ;
Instructions on use and documentation of home glucose monitoring results ;
Low blood glucose information sheet which delineates the s ymptoms of 
hypoglycemia along with treatment options andinstructions to share with their 
family  member(s) / roommate(s) to help in their management of h ypogl ycemia;
Recommended frequency for routine home glucose monitoring will be determined 
for each subject b y the investigator, however, a frequency  of atleast once per 
dayshould be emphasized;
Home glucose monitoring must be undertaken in the event subjects’ experience 
symptoms of HAE , whenever possible; these s ymptoms must be captured in the 
diary .
Routine safety  monitoring (eg, liver function monitoring) for any  background 
medications, including anti- diabetic agents, is the responsibility  of the investigator 
and should be consistent with guidelines found in prescribing information for the 
respective agents;
Wherever possible , new agents for gl ycemic control or change in doses of 
concomitant agents for glycemic control (refer to Section 5.8.1) should be avoided 
during participation in the study  unless protocol -
specific criteria for inadequate 
glycemic control are met – refer to Section 7.9.3.1.
7.9.3.1. Protocol -
Specific Criteria for Inadequate Glycemic Control
Investigators must review the diary completed b y the subjects and the readings stored in the 
glucometer devices at each visit after the Run -in Visit.  B ased on this information, as well as 
review of the results reported by  the central laboratory , an assessment of any  symptomatic 
and as ymptomatic occurrence of h ypo-or hyper-glycemia must be undertaken. 
7.9.3.1.1. Management of Hypoglycemia (HAE)
Any episode of HAE must be captured with sufficient detail as outlined in Appendix 4.  For 
definition of HAE and severity  categorization, refer to Section 7.9.3.1.2, below. 
7.9.3.1.2. Definition and Severity Categorization of HAE
Based on review of the subject completed diary at each visit to the site as well as results 
reported b y the central laboratory , the investigator must assess the glucose values as well as 
any symptoms d ocumented . 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 71HAE is defined as one of the following:
1.Asymptomatic hypoglycemia: An event not accompanied by  typical symptoms of 
HAE but a plasma glucose reading of 49mg/dL  (2.7 mmol/L ) using 
sponsor -provided, plasma -referenced , home glucometers ( or spons or - identified 
central laboratory );
2.Documented symptomatic hypoglycemia: An event during which ty pical sy mptoms 
of HAE are accompanied with a glucose reading of < 70 mg/dL  (3.9 mmol/L) using 
sponsor -provided, plasma -referenced , home glucometers (or sponsor -identified 
central laboratory )andthe c linical picture include s prompt resolution with food 
intake, subcutaneous glucagon, or intravenous glucose ;
3.Probable symptomatic hypoglycemia: An event during which sy mptoms of HAE
are notaccompanied b y a plasma glu cose determination, but was presumably caused 
by a plasma glucose concentration of < 70 mg/dL (3.9 mmol/L) using 
sponsor -provided, plasma -referenced , home glucometers (or sponsor -identified 
central laboratory )andthe c linical picture include sprompt resol ution with food 
intake, subcutaneous glucagon, or intravenous glucose .
NOTE : Pseudo -hypogl ycemia: An event during which sy mptoms consistent with HAE are 
reported along with a plasma glucose reading  70mg/dL  (3.9 mmol/L) using 
sponsor -provided, plasma -referenced , home glucometers (or sponsor -identified central 
laboratory )may be reported as an adverse event ( AE)of HAE but will notbe considered as 
having met the protocol definition of HAE offered above.
Each episode of HAE must be characterized with respe ct to severit y.  In order to characterize 
the event as ‘ severe ’, all three (3) criteria below must be met:
1. The subject was unable to treat him/herself.  Neurologic impairment, and not the age 
of the subject, is the explanation for wh y the subject could not treat him/herself and 
required the assistance of another person.
2.The subject exhibited at least oneof the following neurological s ymptoms:
Memory  Loss;
Confusion;
Uncontrolled behavior;
Irrational behavior;
Unusual difficulty  in awakening;
Suspected seiz ure;

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 72Seizure;
Loss of consciousness.
3.Either :
Ifblood glucose was measured andwas 49mg/dL  (2.7 mmol/L) using 
sponsor -provided, 
plasma -referenced , home glucometers (or central laboratory ) or
Ifblood glucose was not measured, the clinical manifestations were reversed by  oral 
carboh ydrates, subcutaneous glucagon, or intravenous glucose.
Events that do notmeet all the criteria above for ‘severe’ HAE are characterized as ‘mild’ or 
‘moderate’ in severit y. 
7.9.3.1.3. Management of Hyperglycemia
Hypergl ycemia is define d as a glucose reading of > 270 mg/dL  (15mmol/L) using 
sponsor -provided, plasma -referenced, home glucometers (or sponsor -identified central 
laboratory ).
Subjects noted to have afasting plasma glucose value (during home glucose monitoring 
using sponsor -provided, plasma -referenced, home glucometers oras reported by  the 
sponsor -identified central laboratory ) meeting the above definition of h ypergly cemia must be 
instructed to repeat the measurement the next day  (following 8-hour fast except water).  If 
thesecond measurement also meets the above definition, subject
smust be asked to return to 
the site in the next 52days, following 8-hour fast except water, and have blood 
collected for fasting plasma glucose (and shipped to sponsor -identified central l aboratory  for 
analysis).
Ifthe results from the sponsor -identified central laboratory  confirm the readings using 
sponsor -provided, plasma -referenced , home glucometers or a previous result reported b y the 
sponsor -identified central laboratory , the subject must be withdrawn from the study –with 
the reason for withdrawal captured as an adverse event of h yperglycemia .
8.ADVERSE EVENT REPORT ING
In this stud y, the active collection period for adverse events (serious andnon-serious) will 
start at the time indivi dual subjects’ consent to pre -Qualification and continue through to a 
minimum of 28 calendar days after the last dose of the investigational product.  
Treatment -emergent adverse events will be defined as those noted to have an onset or
increase in severit yafter first dose of double -blinded investigational product (at 
Visit 5 /Day 1).

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 738.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Ev ent (SAE) Report Form 
to Pfizer Safety .  These requirements are delineated for 3 types of events: (1) SAEs; (2) 
non-serious adverse events (AEs); and (3) exposure to the investigational product under 
study  during pregnancy  or breastfeeding, and occupationa l exposure. 
Safety Event Recorded on the CRFReported on the CT SAE 
Report Form to Pfizer Safety 
Within 24 Hours of 
Awareness
SAE All All
Non-serious AE All None
Exposure to the 
investigational product 
under study during 
pregnancy or breastfeeding, 
andoccupational exposureAll (regardless of whether 
associated with an AE), except 
occupational exposureExposure during pregnancy, 
exposure via breastfeeding, 
occupational exposure 
(regardless of whether 
associated with an AE)
All observed or volunteered e vents regardless of treatment group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to Pfizer Safety  on the CT SAE Report 
Form within 24 hours of awareness of the event by the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study .  In particular, if the SAE is fatal or life -threatening, 
notification to Pfizer Safety  must be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation tha t the investigator does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(seeSection 8.2.3 below).  I n addition, the investigator may  be requested by  Pfizer Safet y to 
obtain specific follow -up information in an expedited fashion.  This information is more 
detailed than that recorded on the CRF .  In general, this will include a description of the 
event in sufficient detai l to allow for a complete medical assessment of the case and 
independent determination of possible causalit y.  Any information relevant to the event, such 
as concomitant medications and illnesses, must be provided.  In the case of a subject death, a 
summar y of available autopsy
 findings must be submitted as soon as possible to Pfizer 
Safety .  Any  pertinent additional information must be reported on the CT SAE Report Form; 
additional source documents (eg, medical records, CRF, laboratory  data) are to be sent to 
Pfizer Safety  ONLY upon request.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 74As part of ongoing safet y reviews conducted b y the sponsor, an y non -serious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousne ss, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details o n Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs s hould be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject.  In addition, each study subject will be questioned about the 
occurrence of AEs in a non -leading manner.
8.1.3. Withdra
wal f rom the Study Due to Adverse Events (see also Section 6.6) 
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF. 
When a subject withdraws from the study  becaus e of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with 
Section 8.1 above.
8.1.4.
Time Period for Collecting AE/SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subject’s participation in the study  (ie, before undergo ing any  
study -related procedure and/or receiving investigational product), through and including a 
minimum of 28 calendar days after the last administration of the investigational product.
For subjects who fail during the pre -qualification phase or after S creen 1, the active 
collection period ends when the subject is deemed to be notsuitable / eligible for this study  
(ie, screen failure status).
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subject’s participation in the study  (ie, before undergoing any  
study -related procedure and/or receiving investigational product), through and including the 
2ndFollo w-up Visit.  At the 2ndFollow -up Visit, the subject will be contacted by  telephone 
(unless local regulations dictate on -site visit) to inquire about SAEs, including 
hospitalizations and newly  diagnosed chronic medical conditions since 
previous on- site vis it. 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 758.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfize r 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2. Recording Non -serious AEs and SAEs on the CRF
During the active collection period, both non -serious AEs and SAEs are recorded on the 
CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that asse ssment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE report ing requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to s uggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined b y the sponsor.  If the investigator's causality
 assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records. 
In addition, if the investigator determines that an SAE is associated with study  procedures , 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. S ponsor ’s Reporting Requirement s to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 768.2.Definitions
8.2.1. Adverse Events
An AE is any untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes i n phy sical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 77Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuat ion from the study , significant additional concomitant 
drug treatment, or other therap y; and/or
Test result is considered to b e an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (i mmediate risk of death);
Requires inpatient hospitalization or prolongation of existing hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Results in congeni tal anomaly /birth defect.
Orthat is considered to be:
An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threateni ng and/or 
result in death or hospitalization.  However, if it is determined that the e vent may  jeopardize 
the subject, ormay require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
8.2.4. Hospitalization
Hospitalization is def ined as an y initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 78tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency  room visit is asse ssed for medical importance.
Hospitalization does not include the following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulator y procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include:
Admission for treatment of a preexisting condition not associated with the 
development of a new AE o r with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified a dmission during a study  (eg, for a procedure required by  the study  
protocol);
Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a medical AE;
Preplanned treatment s or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject;
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  Howe ver, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and th e resulting appendectomy  should be recorded as treatment of the 
AE.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 798.3.Severity Assessment
If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE.  For purposes of 
consistency , these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODERATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Protocol -Specific Serious Adverse Events
There are no protocol -specified SAEs in this study
.  All SAEs will be reported to Pfizer 
Safety  by the investigator as described in previous section s, and will be handled as SAEs in 
the safet y database.
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show trans ient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug -induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( xULN) should be monitored more frequently  to determine if they  are an “adaptor” or 
are “susceptible.”
In the maj ority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total b
ilirubin (TBili) elevations (>2 xULN) by  several day s 
or weeks.  The increase in TBili ty pically  occurs while AST/AL T is/are still elevated above 
3x ULN (ie, AST/ALT and TBili values will be elevated within the same lab sample).  In 
rare instances, b y the time TBili elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  There fore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other p ossible causes of liver injury  
have been excluded.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 80The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnorm alities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Subjects with AST/AL T andTBili baseline values within the normal range who 
subsequently  present with AST or ALT values >3x ULN anda TBili value >2 xULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 xULN ornot 
available;
For subjects with baseline AST orALT orTBili values above the ULN, the 
following threshold values are used in the definit ion mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values > 2 times the baseline values and> 3x ULN or>8xULN (whichever is 
smaller).
Preexist ing values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least > ULN orif the value reaches >3 xULN 
(whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The subject should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment.
In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include al bumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutamyl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels –refer to
Table 4.  Consideration should also be given to drawing a separate tube of clotted blood and 
an anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the r ecognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreation al drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals , should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary  tract) may  be warranted. 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 81All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the liver function test ( LFT)abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the investigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiol ogy.
8.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24hours of investigator 
awareness.
8.4.3.1. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having b een 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy . 
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.
  In addition, the investigator must submit information 
regarding environmental exposure to a P fizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occu rred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 82Follow -up is conducted to obtain general information on the p regnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.   In the case of a live birth, the structural 
integrity  of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrity  of the term inated fetus should be assessed by  gross visual inspection (unless 
pre-procedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spo
ntaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the investigational product.
Additional information regarding the EDP may  be requested by the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.3.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using 
the CT SAE Report Form.  An exposure during breastfeeding report is not cre ated when a 
Pfizer drug specificall y approved for use in breastfeeding women (eg, vitamins) is 
administered in accord with authorized use.  However, if the infant experiences an SAE 
associated with such a drug’s administration, the SAE is reported together with the exposure 
during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which ma y or may not lead to the occurrence of an AE.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 83An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.4.4. Medication Errors 
Other exposures to the investigational product un der study  may  occur in clinical trial settings,
such as medication errors .
Safety Event Recorded on the CRFReported on the CT SAE Report Form 
to Pfizer Safety Within 24 Hours of 
Awareness
Medication errors All (regardless of whether 
associated with an AE )Only if associated with an SAE
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength. 
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and non -serious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to Pfizer Safe ty within 24 hours on a CT SAE Report 
Form 
only when associated with an SAE .
9. DATA ANALYSIS/STATIS TICAL METHODS
Detailed methodolog y for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a s tatisti cal analysis plan(SAP) , which will be 
maintained by  the sponsor .  The SAP may modify  what is outlined in the protocol where 
appropriate ; however, any  major modifications of the primary  endpoint definition s or their 
analyses will also be reflected in a pro tocol amendment.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 849.1.Sample Size Determination
The sample size for this study  was based on interest to assess a dose -response for effect of 
PF-05221304 on percent change from baseline i n liver fat (entire study  population as well as 
separately in each sub -popu lation in 1sttier stratification )andpercent change from baseline 
in AL T in the 1sttier stratification sub -population of diagnosed/presumed NASH. 
The proposed sample size for this study  is approximately  360 subjects randomized 
(72subjects per arm) to ensure at least 300 subjects (60 subjects per arm) complete the study . 
Thesample size of a minimum of 60completers per arm , was calculated to y ield 
80% power to detect a placebo -adjusted, 
percent change from baseline of 30% in liver fat 
(in entire study  population andin n=30/arm in each sub-population of the 1sttier 
stratification ), using a 1- sided , t-test at level 10%.  The calculation assumes that the standard 
deviati on for liver fat is 7.8% (between- subject) and 6.2% (within- subject).
For the se condary  endpoint of ALT in the 1sttier stratification sub -population of 
diagnosed/presumed NASH , the sample size of a minimum of 30 completers per arm was 
calculated to yield  80% power to detect a placebo -adjusted, percent change from baseline 
in AL T of35%, using a 1- sided, t- test at level 10%.  The calculation assumes that the 
standard deviation for the parameter of placebo -adjusted, percent change from baseline in 
ALT is 55% (between- subject).
Overall, via the planned interim anal ysis (refer to Section 9.5), if the observed standard 
deviation for the liver fat (MRI -
PDFF) and ALT data, based on unblinded review, is greater 
than the assumptions above, the sample size for this study  may be adjusted upward, at 
sponsor discretion, to a maximum o f 500subjects randomized (ie, 100 subjects per arm).
9.2.Efficacy Analysis
9.2.1. Analysis of the Primary Endpoint
The primary  endpoint is placebo- adjusted, percent change from baseline in liver fat (via 
MRI -PDFF ) at Week 16, for the entire stud y population .  A mixed model repeated measure 
(MMRM) anal ysis will be performed with treatment, time and treatment -by-time interaction 
as fixed effects, and subject as a random effect. 
Descriptive summaries of the observed values and percent change from baseline in liver fat 
in each treatment group at each time point will be produced. 
For statistical analy ses, 80% confidence intervals will be produced for the least- square mean 
differences in each treatment group as compare d to placebo.  One sided p -values will be 
display ed for the comparison against placebo with no multiplicity  adjustment made.
Dose-response modeling of the percent change from baseline in liver fat will be explored 
with total daily  dose and time as a continuous variable to characterize and evaluate the 
dose-response relationship. 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 859.2.2. Analysis of Secondary Endpoint
One of the key secondary endpoint is percent change from baseline in ALT at Week 16 in the 
1sttier stratification sub-population of diagnosed/presumed NASH.  An MMRM analysis will 
be performed with treatment, time and treatment-by-time interaction as fixed effects, and subject as a random effect. 
Descriptive summaries of the observed values and percent change from baseline in ALT in 
each treatment group at each time point will be produced. 
For statistical analyses, 80% confidence intervals will be produced for the least-square mean 
differences in each treatment group as compared to placebo.  One sided p-values will be displayed for the comparison against placebo with no multiplicity adjustment made.
Dose-response modeling of the percent change from baseline in ALT, the 1
sttier stratification 
sub-population of diagnosed/presumed NASH, will be explored with total daily dose and time as a continuous variable to characterize and evaluate the dose-response relationship; assessment of dose-response for effect on ALT for the entire entire study population, may be considered, depending on the data. 
9.3. Analysis of Tertiary Endpoints
9.3.2. Other Tertiary Endpoints
For continuous endpoints, a MMRM analysis will be performed with treatment, time and 
treatment-by-time interaction as fixed effects, and subject as a random effect.  Two-sided p-values and 80% confidence intervals will be displayed for the least-square mean difference or ratio (for natural log-transformed endpoints) against placebo.  Descriptive summaries of the observed values and change from baseline in each treatment group at each time point will also be produced. 
Depending on the observed data at the end of the study and when applicable, dose-response 
modeling of the tertiary endpoints may be explored with total daily dose as a continuous variable to characterize and evaluate the dose-response relationship. 
Descriptive summary (number and percentages) will be displayed for categorical endpoints.CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 869.4. Safety Analysis
Treatment-emergent AEs, as well as SAEs/deaths, clinical safety-related laboratory tests, 
12-lead ECG data, as well as vital signs will be summarized descriptively as appropriate for Pfizer data standards.  Statistical inference may be determined for safety measures of clinical concern.  Safety data will be presented in tabular and/or graphical format and summarized descriptively, as appropriate to Pfizer standards.
Physical exam information collected during the course of the study will not be captured for 
inclusion into the study database, unless otherwise noted.  However, any untoward findings identified on physical exams conducted after the administration of the first dose of blinded investigational product will be captured as an adverse event, if those findings meet the definition of an adverse event as defined in Section 8 .
9.5. Interim Analysis
Interim analysis (IA) will be performed at least once while the study is on-going.  This 
review will include an assessment of the observed safety, and observed (versus assumed) variability for the primary endpoint (liver fat via MRI-PDFF) as well as key secondary endpoint (ALT).  The 1 planned IA is proposed after at least one-third of the total planned 
randomized subjects (ie, approximately 120 subjects), complete through at least one-third of 
the total dosing duration (ie, Visit 8 [Week 6] ) of the study. Interim analysis results may be 
used for conducting a sample size re-estimation, stopping a dose-level for observed safety, facilitate  and internal business decisions regarding planning of future trials with PF-05221304. Before any interim analysis is instigated, the details of the objectives, decision criteria, dissemination plan, and method of maintaining the study blind as per Pfizer’s standard operating procedures (SOPs) will be documented and approved in an IRC charter. In addition, the analysis details will be documented and approved in an interimanalysis SAP or final SAP.
9.6. Data Monitoring Committee 
This study will not
use a data monitoring committee. 
An IRC to undertake unblinded review of the safety data and unblinded review of the 
observed standard deviation for the liver fat (MRI-PDFF) and ALT data, is planned while the study is on-going – refer to Section 9.5 .
10. QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during study conduct to ensure that 
the protocol and Good Clinical Practices (GCPs) are being followed.  The monitors may review source documents to confirm that the data recorded on CRFs are accurate.  The investigator and institution will allow Pfizer monitors/auditors or its agents and appropriate regulatory authorities direct access to source documents to perform this verification.  This verification may also occur after study completion.CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 87During study  conduct and/or after study  completion, the investigator site may  be subject to 
review b y the IRB/EC, and/or to quality  assurance audits performed by  Pfizer, or companies 
working with or on behalf of Pfizer, and/or to inspection by  appropria te regulatory  
authorities.
The investigator(s) will notify  Pfizer or its agents immediately  of any  regulatory  inspection 
notification in relation to the study .  Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspection and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection.  The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the stud y 
data and the subje ct's medical records.  The investigator will promptly  provide copies of the 
inspection findings to Pfizer or its agent.  Before response submission to the regulatory 
authorities, the investigator will provide Pfizer or its agents with an opportunity  to review 
and comment on responses to any  such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RECORD KEEPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this stud y.
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropria te regulatory  
authorities, without written permission from Pfizer.
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y, and laboratory data entered on the CRFs and any other data collection forms (source 
documents) and ensuring that they  are accurate, authentic/original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring, and available when required.  The 
CRFs must be signed by  the investigator or by  an authorized staff member to attest that the 
data contained on the CRFs are true.  An y corrections to entries made in the CRFs or source 
documents must be dated, initialed, and explained (if necessary
) and should not obscure the 
original entry . 
In most cases, the source documents ar e the hospital or the phy sician subject chart.  In these 
cases, data collected on the CRFs must match the data in those charts. 
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigat or site and at Pfizer that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 8811.2. Record Retention
To enable evaluations and/or inspections/audits from regulatory authorities or Pfizer, the 
investigator agrees to keep records, including the identity  of all participating subjects 
(sufficient information to link records, eg, CRFs and hospital records), all original signed 
informed consent documents, copies of all CRFs, safet y reporting forms, s ource documents, 
and detailed records of treatment disposition, and adequate documentation of relevant 
correspondence (eg, letters, meeting minutes, and telephone call reports).  The records should 
be retained b y the investigator according to the ICH guidelines, according to local 
regulations, or as specified in the clinical study agreement (CSA), whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period (eg, retirement, relocation), P fizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer, such as another 
investigator, another institution, or an independent third party  arranged by  Pfizer. 
Investigator records must be kept for aminimum of 15 years after completion or 
discontinuation of the study or for longer if required by applicable local regulations.
The investigator must obtain Pfizer's written permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent documents, and other relevant documents, eg, 
recruitment ad vertisements, if applicable, from the I RB/EC.  All correspondence with the 
IRB/EC should be retained in the investigator file.  Copies of I RB/EC approvals should be 
forwarded to Pfizer.
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The s tudy will be conducted in accordance with the protocol, legal and regulatory  
requirements and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH Guideline for Good Clinical Practice, and the Declaration of 
Helsinki.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 8912.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any  reports, publications, or other disclosures, except where 
required b y law. 
When study  data are compiled for transfer to Pfizer and other authorized parties, subject 
names, addresses, and other identifiable data will be replaced b y numerical codes based on a 
numbering sy stem provided by  Pfizer in order to de -identify  study  subjects.   The investigator 
site will maintain a confidential list of subjects who participated in the study, linking each 
subject’s numerical code to his or her actual identity . 
In case of data transfer, Pfizer will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable privacy  laws.
The informed consent documents and an y subject recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws.
The informed consent documents used during the informed consent process and any  subject 
recruitment materials must be reviewed and approved by  Pfizer, a pproved by  the IRB/EC
before use, and available for inspection.
The investigator must ensure that each study  subject is fully  informed about the nature and 
objectives of the stud y and possible risks associated with participation. 
The investigator, or a person designated by  the investigator, will obtain written informed 
consent from each subject before any  study -specific activity  is performed.  The investigator 
will retain the original of each subject's signed consent document .
At the end of the stud y, the investigational product in this study  will notbe provided to the 
subjects who participated.
12.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an appl icable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately. 
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes awa re of.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 9013.DEFINITION OF END OF TRIAL
13.1. End of Trial in a Member State
End of trial in a Member State of the European Union is defined as the time at which it is 
deemed that a sufficient number of subjects have been recruited and completed the study  as 
stated in the regulatory  application (ie, clinical trial application [CTA]) and ethics application 
in the Member State.  Poor recruitment (recruiting less than the anticipated number in the 
CTA) by  a Member State is not a reason for premature termination but is con sidered a 
normal conclusion to the study  in that Member State.
13.2. End of Trial in All Other Participating Countries
End of trial in all other participating countries is defined as last subject last visit (L SLV)
reflected b y completion of the 2nd Follow -up visit for the last subject randomized in the 
study . 
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the IRB/EC, or investigational product safety  problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
PF-05221304 at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.  After 
notification, the investigator must contact a ll participating subjects and the hospital pharmacy  
(if applicable) within 28calendar days .  As directed by  Pfizer, all study  materials must be 
collected and all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly disclose clinical trial results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations. 
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the count ry in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer -sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
Pfizer prod uct, regardless of the geographical location in which the study  is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pedia tric 
populations.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 91PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes of final collection of data for the primary  outcome, whether the clinical study  
concluded according to the prespecified protocol o r was terminated.
EudraCT
Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in ad ult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed ) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publi cation by  the 
principal investigator (PI) of the results of the study  based on information collected or 
generated b y the PI , whether or not the results are favorable to the Pfizer product.  However, 
to ensure against inadvertent disclosure of confidential 
information or unprotected 
inventions, the investigator will provide Pfizer an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the study (collectively, “ publication”) 
before it is submitted or otherwise disclose d.
The investigator will provide any  publication to Pfizer at least 30 days before 
it is submitted 
for publication or otherwise disclosed.  If any patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the discl osure for a period not to exceed an 
additional 60 days.
The investigator will, on request, remove an y previously  undisclosed confidential 
information before disclosure, except for an y study -or Pfizer product -related information 
necessary  to the appropriate scientific presentation or understanding of the study  results.
If the stud y is part of a multicenter study, the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent publicati ons 
by the 
PIwill reference that primary  publication.  However, if a joint manuscript has not 
been submitted for publication within 12 months of completion or termination of the study  at 
all participating sites, the investigator is free to publish separat ely, subject to the other 
requirements of this section.
For all publications relating to the study , the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 92Publication of study  results is also provided for in the CSA between Pfizer and the 
institution.  I n this section entitled Publications by  Investigators, the defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of study  subjects, and the CSA will control as to all other 
issues.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 9316. R EFERENCES
1. Saggerson D. Malon yl-CoA, a key  signaling molecule in mammalian cells. Annu Rev 
Nutr 2008, 28, 253-72.
2.
LaBrecque D, Abbas Z, Anania F, et al. Nonalcoholic fatty  liver disease and 
nonalcoholic steatohepatitis. I n: WGO Global Guidelines NAFLD/NASH (long 
version). Milwaukee, WI: World Gastroenterology  Organisation; 2012: 29 pages.
3. Sany al AJ, Friedman SL , McCullough AJ, et al. Challenges and opportunities in drug 
and biomarker development for nonalcoholic steatohepatitis: findings and 
recommendations from an American Association for the Study  of L iver Diseases -U.S. 
Food and Drug Administration Joint Workshop.  Hepatolog y2015; 61(4):1392-405.
4. Khan F, Perumpail R, Wong R, et al. Advances in hepatocellular carcinoma: 
Nonalcoholic steatohepatitis -related hepatocellular carcinoma. World J Hepatol 
2015; 7(18):2155-61.
5. Younossi Z, Koenig A, Abdelatif D, et al. Global epidemiology  of nonalcoholic fatty  
liver disease –meta -analy tic assessment of prevalence, incidence, and outcomes.  
Hepatolog y 2016;64(1):73-84.
6. Noureddin M, Anstee Q, Loomba R.  Review article: emerging anti-fibrotic therapies in 
the treatment of non -alcoholic steatohepatitis.  Aliment Pharmacol Ther 
2016;43(11):1109 -23.
7. L aBrecque D, Abbas Z, Anania F, et al. Nonalcoholic fatty  liver disease and
nonalcoholic steatohepatitis. I n: WGO Global Guidelines NAFLD/NASH (long 
version). Milwaukee, WI: World Gastroenterology  Organisation; 2012: 29 pages.
8. Lambert JE, Ramos -Roman MA, Browning JD, et al. Increased de novo lipogenesis is a 
distinct characterist ic of individuals with nonalcoholic fatty  liver disease. 
Gastroenterolog y 2014 ; 146(3):726 -35.
9. Savage DB, Choi CS, Samuel VT, et al. Reversal of diet -induced hepatic steatosis and 
hepatic insulin resistance by  antisense oligonucleotide inhibitors of acet yl-CoA 
carbox ylases 1 and 2. J C linical Invest2006; 116(3):817 -24. 
10. Schreurs M, van Dijk TH, Gerding A, et al. Soraphen, a n inhibitor of the acet yl-CoA 
carbox ylase s ystem, improves peripheral insulin sensitivity  in mice fed a high- fat diet. 
Diabetes Obes Me tab 2009; 11(10):987-91.
11. Esler WP, Turner, SM, Amor PA, et al. Effects of acetyl-CoA c arbox ylase inhibition on 
lipid metabolism in rodents and human subjects. In: American Diabetes Association 
75th Scientific Session ; 5-9 Jun 2015; Boston, MA, 2015. Abstr.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 9412. Harriman G; Greenwood J, Bhat S, et al. ND -630, a potent and liver- directed 
acetyl-CoA 
carbox ylase inhibitor, r educes hepatic steatosis and improves dyslipidemia 
in diet- induced obese and diabetic rat models of non-a lcoholic fatty liver disease. In:
Keystone Sy mposi a;01-06 Mar 2015 ; British Columbia, Canada. 2015: Abstr .
13. Berod L , Friedrich C, Nandan A, et al. De novo fatty  acid s ynthesis controls the fate 
between regulatory  T and T helper 17 cells. Nat Med 2014; 20(11) :1327 – 33.
14. Rau M, Schilling AK, Meerte ns J, et al. Progression from nonalcoholic fatty  liver to 
nonalcoholic steatohepatitis is marked by  a higher frequency  of Th17 cells in the liver 
and an increased Th17/resting regulatory  T cell ratio in peripheral blood and in the liver. 
J Immunol 2016; 196(1):97 –105.
15. Hernaez R, L azo M, Bonekamp S, et al.  Diagnostic accuracy  and reliability  of 
ultrasonograph y for the detection of fatty  liver: A meta -analysis.  Hepatology  
2011;54:1082
-90. 
16. Neuschwander -Tetri BA, Clark JM, Bass NM, et al.  Clinical, L aboratory  and 
Histological Association in Adults with Nonalcoholic Fatty  Liver Disease.  Hepatology  
2010;52:913 -24. 
17. Schomaker S, Warner R, Bock J, et al.  Assessment of emerging biomarkers of liver 
injury  in human subjects. Toxicol Sci 2013;132(2):276 -83.
18. Chalas ani N, Younossi Z, L avine J E, et al. The diagnosis and management of 
non-alcoholic fatty  liver disease: practice Guideline by  the American Association for 
the Study  of Liver Diseases, American College of Gastroenterolog y, and the American 
Gastroenterologic al Association. Hepatology . 2012; 55(6) :2005 - 23.
19. Petit JM, Cercueil JP, L offroy  R, et al.  Effect of liraglutide therap y on liver fat content 
in patients with inadequately  controlled t ype 2 diabetes. The Lira -NAFLD study .  J Clin 
Endocrinol Metab 2017; doi :10.1210/jc.2016 -2775.

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 95Appendix 1. Abbreviations 
This following is a list of the abbreviations that may be used in this document.
Abbreviation Term
%CDT Percent Carbohydrate deficient transferrin relative to total transferrin
β-hCG Beta-human chorionic gonadotropin
A1AT Alpha-1-antitrypsin
Abs absolute
ACC acetyl-CoA carboxylase
AE adverse event
ALT / SGPT alanine aminotransferase / serum glutamic pyruvic transaminase
AST / SGOT aspartate aminotransferase / serum glutamic oxalo-acetic transaminase
ATP adenosine triphosphate
AUC area under the curve (used when referring to PK)
AUC 24 area under the concentration-time curve from time 0 to 24 hours
AUC inf area under the concentration-time curve from time 0 to infinity
AUC last area under the concentration-time curve from time 0 t o the time of the last quantifiable concentration
AUC tau area under the concentration-time curve from time 0 to time t
AUDIT Alcohol use disorders identification test
AUEC Area under effect curve (used when referring to drug response)
BID bis in die
BLQ below the limit of quantification
BMI body mass index
BP blood pressure
BUN blood urea nitrogen
CAPTMControlled attenuation parameter
CK creatine kinase
CK18-M30 cytokeratin-18-M30 sub-species
CK18-M65 cytokeratin-18-M65 sub-species
Cmax peak or maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
CPT-1 carnitine-palmitoyl transferase 1
CSA clinical study agreement
CSR clinical study report
CT clinical trial
CTA clinical trial application
CYP3A Cytochrome P-450 3A
D2O/  2H2O deuterium oxide / deuterated water 
dB/m decibels per meter
DBP diastolic blood pressure
DCT data collection tool
DDI Drug-drug interaction
DILI drug-induced liver injury
DMC data monitoring committee
DNA deoxyribonucleic acid
DNL de novo lipogenesis
DPP-IVi Dipeptidyl peptidase-IV inhibitors
DU Dispensing Unit
EC ethics committee
ECG electrocardiogram
e-CRF Electronic case report form
EDP exposure during pregnancy
EDTA edetic acid (ethylenediaminetetraacetic acid)CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 96Abbreviation Term
eGFR Estimated glomerular filtration rate 
EIU exposure in utero
ET Early Termination
EU European Union
EudraCT European Clinical Trials Database
FA flip angle
FDA Food and Drug Administration
FFA free fatty acid
FIH first-in-human
FPG Fasting plasma glucose 
FPI Fasting plasma insulin
FSH follicle-stimulating hormone
FU Follow-up
GCP Good Clinical Practice
GGT Gamma-glutamyl transferase
GLDH Glutamate dehydrogenase
GLP Good Laboratory Practice
GLP-1r glucagon-like peptide-1 receptor
HAE Hypoglycemia
HbA1C Glycated hemoglobin
HBsAg hepatitis B surface antigen
HBV Hepatitis B virus 
HCC Hepatic Cellular Carcinoma
HCV Hepatitis C virus
HCV RNA Hepatitis C virus genetic material (ie, Ribonucleic acid)
HCVAb hepatitis C antibody
HDL-C high density lipoprotein cholesterol
HIV human immunodeficiency virus
HOMA-IR Homeostatic model assessment of insulin resistance
hr hour
ht height
IA Interim Analysis
IB Investigator’s brochure
ICH International Conference on Harmonisation
ID identification
IND investigational new drug application
INR international normalized ratio
IOP in- and out-of-phase
IP investigational product
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IWR interactive web response
kPa kilopascals
LDL-C low density lipoprotein-cholesterol
LFT liver function test
LLN lower limit of normal
LSLV last subject last visit 
LSM Liver stiffness measure
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentrationCCI
CCI
CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 97Abbreviation Term
MCV mean corpuscular volume
MDR1 multi-drug resistance protein-1
MDRD Modification of Diet in Renal Disease
MEC molar extinction coefficient
MedDRA medical Dictionary for Regulatory Activities
MELD model of end-stage liver disease
min minute
MMRM Mixed model repeated measure 
MRI-PDFF Magnetic resonance imaging using proton density fat fraction acquisition
MRS Magnetic resonance spectroscopy
MSDS material safety data sheets
MTD Maximum tolerated dose 
N/A not applicable
NAFLD nonalcoholic fatty liver disease
NASH Nonalcoholic steatohepatitis
NGSP National Glycohemoglobin Standardization Program 
NOAEL no observed adverse effect level
NOEL no observed effect level
NSAIDS Non-steroidal anti-inflammatory medications
NYHA New York Heart Association
OATP organic anion-transporting polypeptide
OEB5 occupational exposure banding 5
PBPK physiologically based pharmacokinetic
PCD primary completion date
PCSK9 proprotein convertase subtilisin/kexin type 9
PD Pharmacodynamics(s)
PE physical exam
PI Principal investigator
PK pharmacokinetics
PNPLA3 Patatin like phospholipase domain containing protein 3
pre-Q Pre-qualification visit 
ProC3 N-terminal pro-peptide of type III procollagen
ProC6 C-terminal fragment of α3 chain of procollagen type VI  (also known as Endotrophin)
PT prothrombin time
PTR peak to trough ratio
Q12H Every 12 hours (eg, dosing)
QC quality control
QD quaque die
QTc corrected QT
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SBP systolic blood pressure
SC subcutaneous
SCr serum creatinine
SEM standard error of mean
SOP standard operating procedure
SRSD single reference safety document
SSID Study-specific Subject identification
SUSAR suspected unexpected serious adverse reactionCCI
CCI
CCI
CCI
CCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 October 2017
Page 98Abbreviation Term
T1/2 terminal half-life
T2DM type 2 diabetes mellitus
TBili total bilirubin
TEAE Treatment-emergent adverse event
TG triglycerides
Th17 T helper 17
THC tetrahydrocannabinol
Tmax time to reach maximum concentration
Treg regulatory T
TZDs thiazolidinediones
ULN upper limit of normal
US United States
V Visit
VCTE Vibration-Controlled Transient Elastography 
VLDL very low density lipoprotein
Vz/F apparent oral volume of distribution
w/v weight per volume
WBC white blood cell
WOCBP Women of childbearing potential
wt WeightCCI
PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 99Appendix 2. Guidance to Investigators – Management of Individual Subjects With 
Decrease in Platelet Count
Platelet Count result at Visits starting at Visit 5 / Day 1 to Visit 1 1 / Week 16, inclusive, 
as assessed via Sponsor -identified central laboratory is…
Was Scheduled Visit result representing 
a continued decline relative to result(s) 
from prior visit(s)?
Yes No
Arrange for an unplanned visit within 5 ±2 days 
of receipt of results from scheduled visit
Collect hematology panel≥75,000 / mm3
And < 100,000 / mm3<75,000 / mm3
Subject to return for next 
Scheduled VisitWas Scheduled Visit result representing 
a continued decline relative to result(s) 
from prior visit(s)?
Yes No
Ifunplanned visit result is…
•≥ 75,000 / mm3And< 100,000 / mm3
• Subject to return for next scheduled visit 
•At Investigator discretion , additional unplanned visit(s) before next Scheduled Visit permitted
•< 75,000 / mm3
•Subject should be withdrawnSubject should 
be withdrawn
NOTE : If at Week 8 (V9) platelet count is observed to be below lower limit of normal as reported by sponsor -identified central 
laboratory, visits should occur at W eek 10 ±4 days (unplanned), Week 12 ±4 days (V10), Week 14 ±4 days (unplanned), and 
Week 16 ± 4-days (V11) relative to Day 1 (V5), in order to follow this parameter, closely

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 100Appendix 3.Guida nce to Investigators – Management of Individual Subjects With 
Elevation in Fasting Serum Triglycerides
Serum T riglyceride result at Visits starting at Visit 5 / Day 1 to Visit 1 1 / W eek 16, inclusive, 
as assessed via Sponsor -identified central laboratory is…
Was Scheduled Visit collection post ≥ 8 -hrovernight fast?
Yes No
Arrange for an unplanned visit within 5 ±2 days 
of receipt of results from scheduled visit
Collect lipid panel post ≥ 8 -hrovernight fast≥ 600 and< 800 mg/ dL
[≥ 6.8 and< 9.0 mmol /L]≥ 800 mg/ dL
[≥ 9.0 mmol /L]
Subject to return for next 
Scheduled Visit post ≥ 8 -hr
overnight fastWas Scheduled Visit collection post ≥ 8 -hrovernight fast?
Yes No
Ifunplanned visit result is…
•≥ 600 and < 800 mg/ dL[≥ 6.8 and< 9.0 mmol /L]
• Subject to return for next scheduled visit post ≥ 8 -hrovernight fast
•At Investigator discretion , additional unplanned visit(s) before next Scheduled Visit permitted
•≥ 800 mg/ dL[≥ 9.0 mmol /L]
•Subject should be withdrawnSubject should 
be withdrawn

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 101Appendix 4. Guidance to Investigators – Capturing Details for Episodes of 
Hypoglycemia in Patients with T2DM
The following checklist must be completed by the site staff during each outpatient visit to 
the site based on responses provided b y the subject and where applicable, the adequate 
medical care provided to treat episodes of h ypogl ycemia.
Did the subject have an y symptoms of hy pogly cemia since their last visit 
to the site?
 YES   NO
If yes, did the subject require assistance of another person to activel y administer treatment 
for the event?   YES   NO
Did the subject exhibit any  of the CNS s ymptoms of severe h ypogl ycemia? These include: 
memory  loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty  in 
awakening, suspected seizure, seizure, loss of consciousness.    YES   NO
Was blood glucose measured?  NO  YES
If yes, what was the result? ____  mmol/L   mg/dL ; anddid the result meet threshold for 
severe h ypogl ycemia?  YES   NO
Severe h ypogl ycemia is defined as subject was unable to treat him/her self AND subject 
exhibited CNS sy mptoms of severe hy pogly cemia mentioned above AND either blood 
glucose when measured was 49 m g/dL  (or 2.7 mmol/L) or blood glucose was not measured 
by clinical manifestation reversed by  oral carboh ydrates, subcutaneous glucagon or 
intravenous glucose.
If no , did sy mptoms resolve when treated with carbohy drates, or glucagon?   YES   NO
Did the event awaken the subject while asleep for the night?  YES  NO
What time did the hy pogly cemic event start?  What time did it resolve?  
When was the last meal (of 400 kcals) consumed?  ____ Date; ____ Time
When was the last dose of concomitant medicatio n for gly cemic control taken?  
____ Date; ____ Time
Were an y actions taken?  YES   NO
If yes, dosing with investigational product –choose only  one and enter details in 
concomitant treatment section.
 No action taken  Trial drug stopped temporarily  Trial drug stopped permanentl y

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 102Concomitant treatment dosing –choose only  one and enter details in concomitant treatment
section.
 No action taken   Dose increased   Dose reduced
  Drug stopped temporarily    D rug stopped permanently
Subject was: choose all relevant options and enter details in concomitant treatment section 
if applicable.
 Withdrawn from Trial
 Treatment given (specify  details in concomitant treatment section
 Other (specify ):
 No Action
Does Serious Criteria apply? Serious is defined as fatal, life -threatening, inpatient 
hospitalization or prolongation of existing hospitalization, persistent or significant 
diability /incapability , congenital anomal y/birth defect, important medical event (ie, may  
jeopardize subject and may  require medical/surgical intervention to prevent above listed 
outcomes).  YES 
 NO
Was the event a result of a study  medication error?   YES / UNKNOWN  NO
If yes, complete Medication Error Log.
The following elements must be completed at the time the event resolves or at the end of the 
trial:
Causality: Is there a reasonable possibility  the adverse event is related to trial treatment?
 YES / UNKNOWN  NO
If no, what is the most likely cause of the h ypoglycemic adverse event? Choose one of the 
following:
 Concomitant treatment –drug or nondrug (specify );
 Other (sp ecify ).
If subject experienced s ymptoms of hy pogly cemia, choose all that apply :
 Hunger  Palpitations  Blurred Vision  Headache  Tachy cardia  Disorientation
 Dizziness 
 Tremulousness   Loss of Consciousness  Light Headedness   Irritabil ity 

PF-05221304 
C1171002
FINAL Protocol Amendment 2, 03 Oct ober 2017
Page 103 Seizures  Sweats   Other (specify )
What ty pe of treatment was administered? 
Oral carboh ydrates  YES   NO
Parenteral   YES   NO
Was a precipitating event identified?  YES   NO
If yes, choose all relevant options from the list below:
  M issed Meal/missed snack  Diabetes Medication Error –wrong dose
 Delay ed Meal/delay ed snack   Diabetes Medication Error –wrong time
 Exercise   Other precipitating event (specify )
 Comments
